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Nature has served as source for several bioactive compounds with great chemical diversity, and 
the application of natural products in drug development has been a remarkable success. The 
bioprospecting efforts have previously been concentrated on terrestrial organisms, whereas 
organisms living in marine environments were left largely underutilised. Therefore, marine 
organisms have moved into focus as improvements in technologies have made the marine 
environments more easily accessible (1). 
Bacterial natural products have contributed with a large part of the bioactive compounds that 
lead to drugs, and the biggest portion of the marketed antibiotics are bacterial products or their 
derivatives (2). Marine bacteria are not yet investigated to the same extend as their terrestrial 
counterparts. Therefore, they are considered a promising source for novel bioactive metabolites 
for drug development, which has been a trigger for the work carried out in this thesis. In this 
thesis, three Arctic marine bacteria of the genus Thalassospira, Alteromonas and Pseudomonas 
were investigated. The bacterial strains were cultivated, extracted and pre-fractionated. The 
fractions were screened for antibacterial and anticancer activity, and active fractions were re-
fractionated. The bioactive re-fractionated extracts were dereplicated to investigate if the 
compounds suspected of being active, were novel or had been previously reported. Compounds 
assumed to be bioactive, as well as those with interesting chemical properties were isolated and 
characterised. One bioactive compound was isolated from the bacterial strain Thalassospira sp. 
The compound was active in both antibacterial and anticancer assays, and its structure remains 
to be elucidated. A di-halogenated compound was also isolated from this strain, it was however 
found to be chemically unstable. Moreover, three compounds were isolated from the bacterial 
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1.0 Introduction  
1.1 Natural products 
 
Natural products (NPs) are chemical compounds synthesised by living organisms such as 
plants, animals and microorganisms (3, 4). The term ‘’NPs’’ refers often to secondary 
metabolites, because they are predominantly not biosynthesised by the general metabolic 
pathways as primary metabolites, and they are not required for normal growth, development or 
reproduction of an organism (4, 5). Secondary metabolites are produced by organisms in 
response to needs and challenges of the natural environment, and they provide the producing 
organisms with benefits in various ways, for instance by improving nutrient availability or by 
defending against predation and other environmental stressors (e.g., pigments and compatible 
solutes). These metabolites are often exclusive for a set of species within a phylogenetic group. 
Secondary metabolites usually exhibit some sort of biological activity as they have effects on 
living organisms or living tissues, and these are referred to as bioactive secondary metabolites 
(6-8). The focus of this work is metabolites produced during cultivation of marine bacteria. 
There is an urgent need for new therapeutic agents, particularly novel antibiotics, to fight 
diseases and drug-resistant pathogens that poses threats to the public health. The exploration 
and development of new therapeutic agents from NPs have played a central role throughout the 
development of modern medicine as these products present several advantages when compared 
with synthetic compounds, such as high chemical diversity, binding efficiency and tendency to 
interact with high specificity and potency with biological targets, that makes them favourable 
lead compounds for drug discovery (5, 9, 10). This has resulted in a high variety and number 
of therapeutic compounds being discovered in nature, most of which stem from terrestrial plants 
or microbes. Some examples are the cholesterol-lowering drugs Lovastatin and Simvastatin, 
which are derived from the fungus Aspergillus terrus, the angiotensin-converting enzyme 
(ACE) inhibitors Captopril and Enalapril, which are derived from peptides isolated from the 
venom of the Brazillian pit viper Bothrops jaraca, Amoxicillin (antibiotic) which is derived 
from Penicillium fungi, Phenoxymethyl-penicillin (antibiotic) which is derived from 
Penicillium chrysogenum and Taxol (anticancer drug) which is derived from Taxus brevifolia 
(11-15). The chemical structures of the mentioned compounds can be seen in Fig 1.  
NPs typically contain more complex scaffolds in contrast with synthetic drugs which are 
generally observed as flat, rigid molecules with a high degree of aromatic character. Among 
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other things NPs contain a larger number of ring systems and chiral centres, making them 
sterically more complex structures. In addition, NPs contain a lower number of nitrogens, 
halogen and sulphur atoms, whereas the content of oxygen is higher compared with synthetic 
drugs. NPs also have on average higher molecular weights, lower hydrophobicity and increased 
polarity compared to synthetic drugs. These structural features enable NPs to provide highly 
selective and specific biological activities. For instance, increased content of chiral centres in a 
molecule has been associated with enhanced binding selectivity (15). 
 
Figure 1: Chemical structure of some drugs derived from NPs (12). Lovastatin and simvastatin are derived from the fungus 
Aspergillus terreus (13). Captopril and Enalapril are derived from peptides isolated from the venom of the Brazillian pit viper 
Bothrops jararaca (14). Amoxicillin and Phenoxymethylpenicillin are derived from the fungus Penicillium fungi and 




1.2 The marine environment 
 
Approximately three quarters of the earth’s surface is covered by seas and oceans which 
represent an enormous resource for the discovery of potential therapeutic compounds. The 
marine environment is a relatively untapped reservoir of novel NPs in contrast to the terrestrial 
environment. More than 15,000 structurally diverse NPs with a wide array of bioactivities have 
been discovered from the marine environment since the 1970s (9). There has been a growing 
interest in searching the marine environment for novel bioactive compounds during the last 
decades, due to its enormous variety in habitats with high diversities of organisms (17). The 
marine environment has certain unique characteristics compared to the terrestrial environment, 
such as high salinity, high hydrostatic pressure, high or low temperatures, high salt 
concentrations and low concentrations of organic matter, making the organisms living in marine 
environments metabolically and physiologically different from those living in terrestrial 
environments (18, 19). Nevertheless, it represents a widely unexplored authority for isolation 
of novel microbes like bacteria, fungi, actinomycetes, microalgae-cyanobacteria and diatoms, 
that are potent synthesisers of bioactive secondary metabolites (20). However, the marine 
environment is considered capable to provide new lead compounds against pathogenic 
microbes that are developing resistance to existing pharmaceuticals (21).  
1.3 Marine bioprospecting 
 
Marine bioprospecting is the process of research and development of novel bioactive 
compounds based on marine organisms, including microorganisms like bacteria, fungi and 
viruses as well as macroorganisms such as sea plants, shellfish and fish. The principle of marine 
bioprospecting is to search for components, compounds or genes that can be included as 
components in products or processes. Suitable fields of application may include medicine, 
processing industries, oil and gas, food, feed and biofuels. The marine organisms may stem 
from the sea, the coast, the fjord, the seabed or oil reservoirs beneath the seabed (22). This 
thesis will focus on the use of marine natural products (MNPs) as lead compounds with 
potential for further development into antibiotics and drugs for anticancer treatment.  
Marine organisms represent abundant sources of structurally diverse bioactive compounds with 
various and often potent biological activities, many of which belong to new chemical classes 
not found in terrestrial NPs (23, 24). The first antibiotic of marine microbial origin, 
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pentabromopseudilin, isolated from the bacteria Pseudomonas bromoutilis in 1966, has a 
unique highly brominated chemical structure not seen in the products of terrestrial origin (Fig. 
2) (18).  
 
Figure 2: Chemical structure of an antibiotic produced by the marine bacteria Pseudomonas bromoutilis (18). 
1.4 Marine natural products  
 
Marine organisms are known to produce a wide array of secondary metabolites to ensure their 
survival, persistence and competitiveness in diverse and hostile habitats, some of which can be 
used as lead compounds in the development of new pharmaceuticals (5, 25, 26). They are in 
general rich sources of pharmacologically active compounds with great chemical diversity and 
complexity (27). The chemical diversity associated with compounds derived from marine 
sources is boundless, differing from simple linear peptides and fatty acids to complex alkaloids, 
terpenes and polyketides (28). These structurally distinct molecules have been reported to have 
various bioactive properties such as anticancer, anti-inflammatory, anti-proliferative, cytotoxic 
and antibiotic properties (20, 28). Some of these compounds possess novel mechanisms of 
action. For example, the anticancer agent trabectedin (Yondelis®; Fig. 3) derived from the 
marine tunicate Ecteinascidia turbinate, shows a unique and complex mechanism of action 
causing DNA damage and distinctively interferes with the transcription-coupled nucleotide 
repair system by binding to the DNA minor groove, resulting in apoptosis in cancer cells that 
show highly accelerated gene expression compared with normal cells (29).  
 
Figure 3: Chemical structure of trabectedin (30). 
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One of the first MNPs to enter clinical trials as an anticancer agent was Didemnin B (Fig. 4), 
isolated from the tunicate Trididemnum solidum (31, 32). However, the compound did not make 
it to the market as it turned out to be too toxic for safe use (33). Despite the fact that Didemnin 
B was not successfully developed into a drug, since then a plethora of drug candidates have 
been isolated from marine organisms, and interest has slowly shifted from terrestrial to marine 
bioresources due to the adventitious properties afforded by the MNPs (31, 34). Marine-derived 
compounds show higher incidence of significant bioactivity compared to those of terrestrial 
origin (29, 35). For instance, almost 1% of the tested marine samples in a National Cancer 
Institute preclinical cytotoxicity screen showed anticancer potential, whereas only 0.1% of the 
tested terrestrial samples showed anticancer potential (29). Certain pharmaceuticals have been 
developed from lead compounds of marine origin, such as the anticancer drug Cytarabine (Ara-
C®) and the antiviral drug Vidarabine (Ara-A®), which are nucleosides derived from the 
Caribbean sponges Cryptotheca crypta and Tethya crypta, respectively. These were the first 
marine-derived drugs approved by the Food and Drug Administration (FDA) in the United 
States, in 1969 and 1976, respectively. Another  pharmaceutical of marine origin is the peptide 
Ziconotide (Prialt®), derived from the tropical marine cone snail Conus magus, which produces 
the peptide to inactivate its prey. Prialt® was approved by FDA in the United States in 2004 for 
treatment of chronic pain (29, 36, 37). The chemical structures of the mentioned compounds 




Figure 4: The chemical structure of the marine derived compounds Didemnin B (31), Cytarabine (38), Vidarabine (38) and 
Ziconotide (39). 
 
1.5 Marine microbial natural products 
 
Marine microorganisms are currently of considerable interest in discovery of novel 
pharmaceutical lead compounds, as some of the compounds isolated from marine invertebrates 
are suspected of being produced by symbiotic microorganisms rather than the invertebrate 
itself. (25, 40, 41). For example, the potential marine anticancer compound Bryostatin 1 (Fig. 
5) which is currently under Phase II clinical trials, was initially considered to be synthesised by 
Bryozoa. However, recently it has been confirmed that it is actually synthesised by the bacterial 
symbiont, Candidatus Endobugula sertula (20). Another example is that the antifungal 
compound Theopalauamide (Fig. 5), isolated from the sponge Theonella swinhoei, was also 
found to be associated with fractions from the δ-Proteobacterium Entotheonella palauensis 




Figure 5: The chemical structure of the potential anticancer compound Bryostatin 1 (20) and the antifungal compound 
Theopalauamide (41).  
 
In recent years, there has been growing awareness that the most productive source of unique 
NPs is actually microorganisms, including actinomycetes, cyanobacteria and microalgae such 
as dinoflagellates (36). However, it is estimated that less than 5% of marine microbial species 
are identified yet, indicating that the microbial diversity of oceans is still insufficiently 
understood (42). It is also estimated that less than 0.1% of all the microorganisms existing in 
the oceans have been explored till now and among them, only a small fraction have been 
cultivated in the laboratory due to the lack of knowledge concerning nutritional needs and 
environmental requirements of these organisms (43). Nevertheless, marine microbial natural 
products (MMNPs) are now promoted to be pharmaceutically important lead compounds, due 
to improving knowledge of the groups of bacteria and other microbial sources existing in the 
oceans, and the rapid development of novel technologies and tools, such as advances in 
bioinformatics and analytical techniques (20, 44, 45). Several potential pharmaceuticals from 
marine microbial sources with various bioactivities are at different stages of clinical testing 
currently (46). For instance, the proteasome inhibitor Salinosporamide A (NPI-0052: Fig. 6) 
isolated from the marine bacterium Salinispora tropica is in Phase I clinical trials for the 
treatment of multiple myeloma, whereas the peptide Plinabulin (NPI-2358: Fig. 6) developed 
from the fungal diketopiperazine halimide, derived from a marine fungus Aspergillus sp. is 
currently in Phase III clinical trials for the treatment of non-small cell lung cancer. Other 
examples are the promising anticancer compounds Tasidoton (ILX-651: Fig. 6) and Solidotin 
(TZT 1027: Fig. 6) which are both isolated from marine bacteria. They are currently under 
Phase II and Phase III clinical trials, respectively (20, 47). Fig. 7 gives an overview of the 
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numbers and the proportion of bioactive/non-bioactive compounds discovered from various 
marine organisms between 1985 and 2012, illustrating that the highest proportion of bioactive 
compounds were discovered from marine bacteria and actinomycetes (48). MMNPs represent 
a promising source for drug discovery, in particular for antibacterial and anticancer drugs (49).  
 
Figure 6: The chemical structures of Tasidotin, Plinabulin, Soblidotin and Salinosporamide A (20). 
 
 
Figure 7: Number and proportion of bioactive and non-bioactive compounds discovered from marine organisms between 






1.6 Bacteria  
1.6.1 The bacterial growth curve 
 
The bacterial growth curve represents changes in quantity of a bacterial population over 
time in a batch culture, which is a closed system. Bacteria are not able to grow exponentially 
endlessly in such a system, since parameters necessary for growth such as pH, temperature, 
concentrations of nutrients, metabolic products and oxygen, change during the different 
growth phases of a batch culture. After a period of time, a negative feedback between 
growth rate and one or several of these parameters in the culture will lead to a steady number 
of cells and will eventually result in a decrease in cell number (50, 51).   
The bacterial growth curve consists of four distinct phases, which are the lag phase, the   
exponential (log) phase, the stationary phase and the death phase. The lag phase is the first 
phase observed in a batch system. In this phase, the bacteria are inoculated into the culture 
medium and they start producing necessary primary metabolites such as enzymes needed 
for their growth in the particular medium (50). Subsequently after the lag phase comes the 
exponential phase, where the bacteria rely on available resources to maintain exponential 
growth. This phase continues until nutrients are reduced or toxic products increase and other 
environmental parameters like temperature and pH value change, at which the rate of 
exponential growth slows, and the bacteria enter the stationary phase. In the stationary 
phase, the bacterial growth reaches a steady state where there is neither an increased nor a 
reduced number of cells. Bacteria synthesise secondary metabolites through this phase of 
the growth cycle (52). In the end, the bacteria enter the death phase due to unfavourable 
conditions. Fig. 8A presents the distinct phases of bacterial growth curve in culture medium 
(53). Temperature and other environmental parameters affect the growth rate of bacteria. 
Bacteria grow at different temperatures depending on the conditions in the natural 
environment of the organism, and they can be classified based on the temperature range at 
which they can grow (Fig. 8B). Bacteria classified as psychrophiles grow at low 
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temperatures, mesophiles grow at moderate temperatures while those classified as 
thermophiles and hyperthermophiles grow at high temperatures (54).  
 
Figure 8: A) The distinct phases of bacterial growth curve in culture medium (53). B) Growth rate of bacteria as a function of 
temperature (55). 
1.6.2 Marine bacteria  
 
Marine bacteria may live in unique and extreme habitats with exclusive circumstances of pH, 
temperature, pressure, oxygen, light, nutrients and salinity, which is particularly rich in chlorine 
and bromine. They are able to sense instantly, adapt, respond to their extreme habitats and 
contend for defence and survival by synthesising attractive unique NPs. Recent advances in 
microbial genomics such as genome sequencing, microbial ecology and metagenomics have 
certainly indicated that the biosynthetic potential of NPs in bacteria is much higher than 
previously acknowledged (56). Marine bacteria thrive in the ocean’s surface waters as well as 
in the lower and immeasurable depths (42). Bacteria that grow in the marine environment are 
generally thermophiles, psychrophiles, mesophiles, halophiles (thriving at high salinity), 
alkalophiles (thriving at high pH), piezophiles (adapted to high pressure) or polyextremophiles 
(adapted simultaneously to several stresses) (19). Thermophilic bacteria grow close to the 
occasional hot thermal vents where hot magma spills out on the seabed (57). However, marine 
bacteria are generally psychrophiles that grow at low temperatures since the average 
temperature of the oceans is below 5 °C (58). Psychrophilic bacteria synthesise enzymes that 
are optimally active at low temperatures, and lose activity at moderate temperatures (59).  
Marine bacteria grow under different conditions, as their nutritional needs and environmental 
requirements vary, and this must be taken into account when cultivating bacteria in the 
laboratory. Many of the marine bacteria require seawater or 3% sodium chloride to freshwater 
in the medium for growth (60). Whereas other marine bacteria require artificial brackish water 
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with various carbon substrates such as agarose, starch, laminarin, xylan, chitin and glucose for 
growth. It is essential to mimic the natural environment for bacteria to grow and produce 
secondary metabolites in culture medium (9).  
1.6.2.1 Alteromonas sp.  
 
Alteromonas is a genus consisting of Gram-negative, rod shaped, aerobic, moderately 
halophilic bacteria with polar flagellum motility. Members of the genus Alteromonas occur 
globally in the surface as well as the deep seawater, and have been isolated from temperate or 
tropical seas and thus are generally mesophiles growing between 10 and 45 °C. Some of the 
species are also psychrophiles that have been isolated from habitats featuring cold temperatures 
such as Alteromonas stellipolaris and Alteromonas litorea (61). Furthermore, the members of 
this genus are considered typical fast growing ‘’blooms’’ that can be easily isolated and 
cultivated in the laboratory (62, 63). However, they depend on the presence of organic nutrients 
in the marine setting for growth (64).  
1.6.2.2 Pseudomonas sp.  
 
Bacteria of the genus Pseudomonas are one of the most well-studied species. They occur in 
most environments and considered to be among the most successful phyla of bacteria, based on 
their low nutritional requirements as well as great metabolic diversity, which allows them to 
utilise various organic compounds as a source of both carbon and energy. Members of the genus 
Pseudomonas synthesise a wide variety of secondary metabolites, which are essential for their 
own survival. Hence, the bacteria of the genus Pseudomonas represent an interesting alternative 
for production of various potential beneficial compounds (65). This is a genus consisting of 
Gram-negative, aerobic, motile by one or several polar flagella, non-spore-forming straight or 
slightly curved rod-shaped bacteria (66).  
1.6.2.3 Thalassospira sp.  
 
The genus Thalassospira consists of Gram-negative, motile, vibrio- or spiral-shaped, 
halotolerant and chemoheterotrophic bacteria. Bacteria of this genus are widely distributed in 
various marine environments, such as seawater, sediment and halobios from every ocean and 
sea (67). Some of the spices are psychrophilic or mesophilic that grow at different temperatures 
between 4 and 40 °C with various salt concentrations (68-70). It has been observed that some 
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bacteria within the genus Thalassospira are able to synthesise thalassospiramides, beta-


























2.0 Aim of this work 
 
The overall aim of this work was to isolate and characterise compounds with antibiotic and 
anticancer activity potentially produced by the marine bacteria Thalassospira sp. (M10B738), 
Alteromonas sp. (M09W202) and Pseudomonas sp. (M10B807). 
The key objectives of the thesis were to: 
1. Screen the fractions from bacterial cultures for antibacterial and anticancer activity. 
2. Dereplicate the bioactive fractions to identify the active compounds. 



























This work was conducted at Marbio, and the practical work performed through the project was 
based on their commonly used methods. Marbio is a high throughput analytical platform for 
isolation and screening of secondary metabolites produced by marine organisms. Fig. 9 gives 
an overview of the practical work performed through the project, and the background for each 
of the steps will be described in the subsequent sections.  
 


















3.2.1 Cultivation and extraction 
 
In this work process, three Arctic marine bacteria collected by Marbank, were cultivated in 
different culture media depending on the environmental and nutritional growth requirements of 
the bacteria. Production of secondary metabolites is controlled by the choice of media, 
temperature, aeration and duration of the fermentation (72). After cultivation, secondary 
metabolites synthesised by the bacteria must be extracted from the culture for further separation 
and characterisation. Solid-phase extraction (SPE) was performed using Diaion® HP-20 and 
methanol, for extraction of secondary metabolites from the bacterial culture. Diaion® HP-20 is 
a non-polar copolymer styrene-divinylbenzene adsorbent resin used to adsorb hydrophobic 
compounds such as antibiotics and biomolecules. This resin is recommended for the adsorption 
of solute molecules with molecular weights lower than 20-30 kilodaltons (73).  
3.2.2 Pre-fractionation of the extracts 
 
Crude extracts are a complex mixture of media components, salts, primary and secondary 
metabolites in different concentrations, consequently they are less suitable for instant 
bioactivity screening. It is therefore often required to desalt and fractionate the extract into 
fractions containing compounds of similar characteristics, such as polarity or molecular size 
(74). Pre-fractionation of extracts to reduce chemical complexity increases the hit rates due to 
a higher concentration of the active compound(s) (36). However, it is not appropriate to 
generate many fractions, as it may spread the active compound over so many fractions that the 
fractions containing this compound in low concentrations might not be detected or not show 
any activity in bioassays (75). In this project, the extracts were fractionated into six flash 
fractions.  
The most frequently used pre-fractionation technique to separate compounds in a mixture, is 
liquid chromatography (LC) such as high-performance liquid chromatography (HPLC) or flash 
chromatography. The sample is loaded onto a column where compounds in the sample are 
separated by a gradient of water and an organic solvent, and the retention times of the different 
compounds depend on their interaction with the stationary phase and the mobile phase (75). In 
this project, flash chromatography was applied for the pre-fractionation of the extracts. Flash 
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chromatography can be applied to separate compounds by size, polarity, charge or affinity 
depending on the column material and mobile phases used. Advantages of flash 
chromatography is high loading capacity and low costs. However, it is not expected to provide 
the same resolution or reproducibility as HPLC. This is nonetheless not needed in pre-
fractionation, since a positive hit will nominate the fraction for isolation of the bioactive 
compounds using preparative HPLC Mass Spectrometry (HPLC-MS). The stationary phase 
utilised in this project was Diaion® HP-20SS, a synthetic styrene-divinylbenzene polymer 
adsorbent used for the separation of hydrophobic compounds as well as biomolecules, and the 
compounds were separated by polarity (76).  
3.2.3 Bioactivity screening of flash fractions 
 
Bioassays are performed to evaluate the bioactivities of compounds in a sample, by, for 
example, observing their effects on cell lines or pathogenic bacteria (77). These assays are 
essential for the discovery of new bioactive lead compounds (78). The process of discovering 
a novel lead compound against a selected target for a specific disease normally involves high 
throughput screening (HTS), where a large number of compounds are screened for activity 
against the target (79). In this project, the flash fractions were screened for possible antibacterial 
and anticancer activities.  
3.2.3.1 Antibacterial activity screening  
 
Antibiotics are substances used in the treatment and prevention of infections caused by bacteria. 
The need for novel antibiotics is widespread due to the fact that most pathogenic bacteria that 
cause infections have developed resistance to existing antibiotics. Antibiotic resistance is 
considered to be one of the biggest threats to global health, as many infections such as 
pneumonia and tuberculosis, are becoming more difficult to treat since the antibiotics used in 
their treatment turn into less effective substances (80). Therefore, there has been an increasing 
interest in investigating and developing novel and effective antibiotics from various sources, 
and more emphasis has been placed on antibacterial activity screening. Commonly used 
bioassays are e.g. disk-diffusion, well diffusion and broth or agar dilution (81).  
In this project, the antibacterial activity screening of the fractions was performed using a 
minimum inhibitory concentration (MIC) assay, which is a method used to determine the lowest 
concentration of an antibiotic needed to inhibit the growth of bacteria. MIC assays are 
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commonly used in discovering antibacterial secondary metabolites in both crude extracts and 
fractions (82). The antibacterial activity of the secondary metabolites was assessed against six 
known human pathogens: Staphylococcus aureus (Gram-positive), Enterococcus faecalis 
(Gram-positive), Pseudomonas aeruginosa (Gram-negative), Escherichia coli (Gram-
negative), Streptococcus type B (Gram-positive) and Methicillin-resistant Staphylococcus 
aureus (Gram-positive).    
3.2.3.2 Anticancer activity screening 
 
Cancer is accountable for an estimated 9.6 million deaths in 2018, making it the second leading 
cause of mortality worldwide (83). It is characterised by uncontrolled proliferation of cells due 
to dysfunction of regulatory signalling pathways that are normally under tight control, and can 
spread quickly into surrounding tissues as well as organs and cause damage (84). The most 
common types of cancer are lung, breast, colorectal, prostate, skin and stomach cancer (83).  
Increasing recurrence of cancer and severe adverse effects of chemotherapeutic agents reduces 
the clinical efficacy of a wide range of anticancer drugs currently used. Hence, there is a 
constant need to develop alternative or synergistic anticancer drugs with minimal adverse 
effects (85).  
In this project, an Aqueous One Solution Cell Proliferation assay was applied to screen the 
fractions for anticancer activity. This is a colorimetric method used to determine if the test 
fractions inhibit cell proliferation or display direct cytotoxic effects that eventually lead to cell 
death, by measuring cell viability (86, 87). The assay contains a tetrazolium salt, called MTS 
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium 
salt (87). Metabolically active cells are able to reduce this salt into a dark blue coloured 
formazan product, and the quantity of formazan that is produced is directly proportional to the 
level of viable cells. Formazan absorbs light at 490 nm and can be determined 
spectrophotometrically (86, 87).  
3.2.4 Re-fractionation of active flash fractions 
 
The active flash fractions were re-fractionated in order to isolate the bioactive compounds using 
preparative HPLC-MS (Fig. 10). There is a wide range of compounds in the active flash 
fraction. Hence, it is necessary to fractionate it further in order to identify the active compounds. 
Reversed phase HPLC-MS (RP-HPLC-MS) used in the project is particularly well suited to 
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deal with the quantities and polarity of compounds developed for pharmaceutical interest. Thus, 
it is widely used for the purification of NPs from complex mixtures (88). RP columns such as 
C18 are used to separate compounds within a wide range of polarities and molecular masses. 
These columns have a hydrophobic stationary phase and consequently the chromatography is 
based on hydrophobic interactions between the compounds and the stationary phase (74). The 
mobile phase, in which the compounds are eluted, is split by a flow splitter to the fraction 
collector and to the ultraviolet (UV) and MS detectors after separation in the column. The main 
advantage of preparative RP-HPLC-MS is that it is selective, and hence allows for efficient 
separation of compounds with similar masses (88).  
 
Figure 10: Schematic illustration of the preparative-HPLC-MS system used in re-fractionation and for compound isolation in 
this project. The figure is made with inspiration from the reference (71).  
 
3.2.5 Bioactivity screening of subfractions 
 
After re-fractionation, the 40 subfractions obtained were screened for antibacterial and 
anticancer activity as described previously.  
3.2.6 Dereplication 
 
Dereplication is the process of identification of already known bioactive compounds using a 
combination of analytical and spectroscopic methods. This is an essential part of the NP drug 
discovery process to avoid further work on active compounds that are previously known and 
focus effort on the discovery of structurally novel compounds (89). Hence, the dereplication 
process has the purpose of making productive use of often limited resources (4).  
The fractions with confirmed bioactivity were selected for dereplication. The dereplication 
process was performed using Ultra-High-Performance Liquid Chromatography in combination 
with Quadrupole-Time-of-Flight MS (UHPLC-QToF-MS). The instrument consists of five 
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components that can be seen in Fig. 11. The UHPLC unit is separating the compounds within 
the extract chemically and directing them into the electron ionisation source where the 
molecules are ionised (90). ESI may be applied to generate both positive and negative ions (91). 
The ionised analytes are then electrostatically propelled into the mass analyser where they are 
separated according to their mass-to-charge (m/z) ratios (92).  For detection, Quadrupole-Time-
of-Flight (Q-ToF) was applied as it provides high mass accuracy and high mass resolution, and 
thus separates compounds with similar masses efficiently (93). This mass analyser is a variant 
of a triple quadrupole where the third quadrupole is replaced by a ToF analyser. In addition to 
the molecular mass of analytes, the fragment data generated by the collision cell allows a better 
identification of compounds by comparing molecular fragments.  
 
Figure 11: Illustration of the five components of a MS system: sample inlet, ionisation source, mass analyser, detector and 
the data system. 
High resolution MS (HR-MS) in combination with liquid chromatography is a preferred method 
of dereplication in NP drug discovery, since this combination is considered both sensitive and 
suitable for analysing complex mixtures (94). The major advantage of this method is that it can 
provide accurate mass which can be used to calculate the elemental composition, which in turn 
can be used to search databases like MarinLit, Dictionary of Natural Products, ChemSpider and 
SciFinder to identify known compounds (94, 95). Nevertheless, only compounds that are 
identical to those in the databases will be identified using this approach, whereas those that are 
similar but non-identical to existing compounds will not be recognised (94). Moreover, the 
inherent disadvantage of this approach is that database searches provide a list of NPs of which 
molecular mass are similar to the observed one, where the compounds in the list are often false 
positives (96). However, fragmentation patterns of compounds can be used to assist in their 
identification. The fragmentation data can be utilised to search MS/MS libraries such as Global 
Natural Products Social molecular networking (GNPS) (94).  
3.2.7 Upscaling and purification  
 
Some compounds of interest may be challenging to identify, either due to low concentrations 
or interference of other substances which prevent identification with sufficient certainty, thus it 
may be necessary to upscale and purify these compounds in order to identify their chemical 
structures correctly. Purified compounds in amounts ranging from one to a few milligrams are 
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required for identification and characterisation of unknown compounds in NP chemistry (97, 
98).  In this work process, MS guided preparative HPLC (Fig. 10) was utilised to purify and 
isolate the compounds which were found to be promising candidates.  
3.2.8 Bioactivity confirmation of the isolated compounds 
 
The promising isolated candidates from which enough material was obtained, were screened 
for antibacterial activity against the bacterial strain Streptococcus type B, and for anticancer 
activity against the cell line A2058, in order to confirm their activity. The bioactive compounds 
were submitted for structure elucidation by Nuclear magnetic resonance (NMR) spectroscopy. 
3.2.9 Structure elucidation using NMR 
 
NMR remains together with MS the first choice in organic structure elucidation. This approach 
is based on the principle that many atomic nuclei spin about an axis and thus have magnetic 
properties that can be utilised to generate NMR spectra with chemical information. In an NMR 
spectrometer the nuclei in a sample is subjected to radiofrequency radiation from a range of 60 
to 1000 MHz in the presence of an external magnetic field, making the nuclei in the sample 
absorb the energy and consequently spin from the low energy to the high energy state. The 
frequency required for absorption of energy is characteristic of the type of nucleus (e.g., 1H or 
13C) and depends on their chemical environment as well as the strength of the external magnetic 
field, which is measured as an NMR signal (99). Several NMR techniques that yield various 
chemical information are required to propose the structure of compounds, including one-
dimensional (1D) such as 1H DEPT and 13C NMR spectra as well as two-dimensional (2D) such 
as COSY (COrrelation SpectroscopY), HSQC (Heteronuclear Single Quantum Coherence) and 
HMBC (Heteronuclear Multiple Bond Correlation) NMR spectra. 1H and 13C NMR spectra 
yield information about the number and chemical environment of protons and carbons in the 
chemical structure (100, 101). COSY NMR spectrum provides information about the coupling 
between nuclei (102), whereas HSQS and HMBC provide information about the correlation 
between two different nuclei separated by one bond and correlations over multiple bonds, 
respectively (103). 2D NMR techniques are utilised to determine the chemical structure of 
complex compounds. In addition, the MS data can provide an elemental composition and 
further information that may aid to solve the structure. The great advantage of NMR in NP 
chemistry is that the method is non-destructive for the sample (as for example in MS or 
bioassays) and the sample can be recovered by almost 100% after taking up the spectra. 
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3.2.10 Bioactivity screening of target compounds 
 
The target compounds should be screened for bioactivity in various assays in order to 





























4.0 Materials and methods 
 
4.1 Sampling and storage of bacteria 
 
Materials 
Table 1: Equipment used in sampling and storage. 
Equipment Equipment identification Supplier 
Alteromonas sp. M09W202 
Marbank, Institute of Marine Research 
(Norway) 
Pseudomonas sp.  M10B807 
Marbank, Institute of Marine Research 
(Norway) 
Thalassospira sp.  M10B738 
Marbank, Institute of Marine Research 
(Norway) 
Difco Marine Broth 279110 
Becton, Dickinson and Company (New 
Jersey, USA) 
Peptone from casein, enzymatic 
digest 
82303 Sigma-Aldrich (St. Louis, MO, USA) 
Glycerol G5516 Sigma-Aldrich (St. Louis, MO, USA) 
Filtered sea water  - 
Norwegian College of Fishery Science, 
UiT (Norway) 
MilliQ Ultrapure water - Merck KGaA (Germany) 
Sanyo Labo Autoclave - Sanyo Electric Co. (Japan) 
Stuart Heat Stir SB162 - Stuart Equipment (UK) 
 
Three Arctic marine bacterial strains from the Marbank collection were used in this project; 
M09W202 from the genus Alteromonas sp., M10B807 from the genus Pseudomonas sp. and 
M10B738 from the genus Thalassospira sp. The bacteria will be shortened AM for 
Alteromonas, PM for Pseudomonas and TS for Thalassospira throughout the thesis. AM was 
isolated from seawater and collected the 22th of May 2009 in the Barents Sea in Norway with 
the Global Positioning System (GPS) coordinates of 75°38.400000N and 29°43.442561E. PM 
was isolated from a halibut (Hippoglossus hippoglossus) and collected the 16th of April 2010 
in the Norwegian Sea with the GPS coordinates of 67°31.800000N and 13°21.963380E. TS 
was isolated from a sea-mouse (Echinocardum cordatum) and collected the 16th of April 2010 
in the Norwegian Sea with the GPS coordinates of 68°30.000000N and 15°0.279511E. The 
bacteria were classified to genus level based on 16S rDNA sequence analysis by Marbank.  
The bacterial strains were stored in FMAP (diluted Marine Agar-Peptone) medium with 30% 
glycerol at -80 °C. The composition of the medium is listed in Table 4. Glycerol was added to 
the medium, and the solution was autoclaved at 120 °C for 30 minutes. The bacterial stock was 
prepared by stroking the bacteria from freeze stock strains stored at -80 °C on a FMAP-agar 
plate, and the plate was incubated for 3-7 days at 10 °C. A single colony was selected and 
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transferred to 5 mL FMAP medium and incubated for 2-3 days at 10 °C with shaking at 300 
rpm. 500 µL of the culture was transferred to cryo tubes with 1 mL of FMAP medium and 
stored at -80 °C.  
4.2 Preparation of cultivation media 
 
Materials 
Table 2: Equipment used in the preparation of cultivation media. 
Equipment Equpiment identification  Supplier 
D-Mannitol 63560 Sigma-Aldrich (St. Louis, MO, USA) 
Peptone from casein, enzymatic 
digest 
82303 Sigma-Aldrich (St. Louis, MO, USA) 
Malt extract 70167 Sigma-Aldrich (St. Louis, MO, USA) 
Yeast extract Y1625 Sigma-Aldrich (St. Louis, MO, USA) 
D-glucose (dextrose) D9434 Sigma-Aldrich (St. Louis, MO, USA) 
Casaminoacid (casein hydrolase) 22090 Sigma-Aldrich (St. Louis, MO, USA) 
Filtered seawater - 
Norwegian College of Fishery Science, 
UiT (Norway) 
MilliQ water - Merck KGaA (Germany) 
Sanyo Labo Autoclave - Sanyo Electric Co. (Japan) 
Infors HT Multitron Pro  - Infors HT (Switzerland) 
 
Method 
The bacterial strains M09W202, M10B807 and M10B738 were cultivated in three different 
media (Table 3). The composition of each medium is listed in Table 4. All media were sterilised 
by autoclaving at 121 °C for 30 minutes, and they were cooled to room temperature before the 
bacterial strains were inoculated. The media with bacterial strains were incubated at 10 °C and 
shaken at 130 rpm in the shaking incubator for 9, 12 and 32 days, respectively (Table 3).  
Table 3: Cutivation parameters used for the three bacterial strains, including the medium used for each of the strain, 
temperature, shaking speed and time for the cultivation. 
Strain Nr.: Media Temperature and shaking Cultivation time (days) 
M09W202 (X0845) DSGC 10 °C, 130 rpm 9 
M10B807 (X0834B) DM19 10 °C, 130 rpm 32 





Table 4: Contents of the media used for cultivation of the bacterial strains and the medium (FMAP) in which the bacterial 
strains were stored.  
Media Chemicals Amount 
DSGC 
D-glucose (dextrose) 
Casaminoacid (casein hydrolase) 
Filtered seawater 
3.6 g (0.4 %) 




Peptone from casein, enzymatic digest 
MilliQ water 







Peptone from casein, enzymatic digest 
Yeast extract 
MilliQ water 







Difco Marine broth 
Peptone 
MilliQ water 






4.3 Extraction of the bacterial cultures 
 
Materials 
Table 5: Equipment used in the extraction of secondary metabolites from the bacterial cultures. 
Equipment Equipment identification Supplier 
Methanol (MeOH) 20864 VWR International S.A.S (France) 
MilliQ water - Merck KGaA (Germany) 
Cheesecloth filter, fine mesh - Dansk Hjemmeproduktion (Denmark) 
Whatman® qualitative filter 
paper, grade 3 
1003-090 GE Healthcare Life Sciences (UK) 
Biofuge Pico Heraeus centrifuge - 
Thermo Fisher Scientifie (Massachusetts, 
USA) 
Rotary Evaporator (Rotavapor) Laborota 
Heidolph Instruments GmbH & Co. 
(Germany) 
Diaion® HP-20 99611 Sigma-Aldrich (St. Louis, MO, USA) 
Universal Shaker SM 30 - Edmund Buhler GmbH (Germany) 
 
Method 
Diaion HP-20 resin was added to the media 3-4 days before the end of the culture for 
extraction of the secreted secondary metabolites. 12 g of resin Diaion HP-20 was weighed out 
in 100 mL Erlenmeyer flasks. The resin was activated by soaking it in 100% methanol for 
minimum 30 minutes, methanol was then removed carefully and replaced with MilliQ water 
for 15 minutes. MilliQ water was removed before resin was added to the cultures.  
A sample of 400 µL was taken from the cultures for DNA test prior to extraction (section 
4.3.1 ‘’Treatment of DNA sample of bacterial culture’’).  
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The culture medium was removed by pouring it over the filter with resin beads remaining in 
the culture flask, and the resin was washed with 200 mL MilliQ water and filtered through 
cheesecloth mesh. 150 mL of methanol was added to the flasks with resin. The flasks were 
subsequently incubated at room temperature for 1 hour with gentle shaking for extraction of the 
secreted secondary metabolites from the resin. After incubation, the extract was filtered through 
a Whatman filter paper. The resin was extacted two times with methanol as described. A sample 
of 400 µL was taken from the extracts for a MS analysis, and the MS sample was stored at –20 
°C. The extracts were dried under reduced pressure at 40 °C using the rotavapor and stored at 
–20 °C until further use.  
4.3.1 Treatment of DNA samples of bacterial cultures 
 
400 µL of the culture was transferred to an Eppendorf tube and centrifuged for 3 minutes at 
18928 relative centrifugal force (rcf). The supernatant was decanted, and the pellet washed with 
1 mL MilliQ water. The sample was centrifuged for 3 minutes at 18928 rcf again, and the 
supernatant decanted. The Eppendorf tube with the pellet was labelled with bacterial strain and 
stored at -20 °C for identity check of the cultures.  
4.4 Flash chromatography of the extracts 
 
Materials  
Table 6: Equipment used in the pre-fractionation of extracts. 
Equipment Equipment identification Supplier 
Methanol 20864 VWR International S.A.S (France) 
Aceton 34850 Sigma-Aldrich, (St. Louis, MO, USA) 
Diaion® HP-20SS 13615 Sigma-Aldrich (St. Louis, MO, USA) 
MilliQ water - Merck KGaA (Germany) 
Biotage® SP4 Flash Purification 
System 
- Biotage (Sweden) 
Biotage® SNAP Cartridge KP-Sil 
(10 g) 
FSK0-1107-0010 Biotage (Sweden) 
Rotary Evaporator (Rotavapor) Laborota 
Heidolph Instruments GmbH & Co. 
(Germany) 








4.4.1 Preparation of the extracts before flash fractionation 
 
The extracts were weighed and dissolved in 20 mL of 90% methanol before adding Diaion® 
HP-20ss column material. 1.5 g Diaion® HP-20ss resin beads were added for each gram of 
extract. Subsequently, the mixture was dried under reduced pressure at 40 °C using the 
rotavapor.  
4.4.2 Flash fractionation of the extracts 
 
The sample was added to a prepacked SNAP column (see section 4.4.3 ‘’Preparation of SNAP 
columns for flash fractionation’’) when it was completely dry and run on the Flash Purification 
system with MilliQ water, methanol and acetone mobile phases using the gradient presented in 
Table 7. The flow rate was 20 mL/minute and each fraction consisted of 80 mL. From pre-
fractionation, six fractions (F1-F6) divided in 27 flash tubes were obtained (Table 7).  
Table 7: Mobile phase gradient used with the flash purification system for the prefractionation of the extracts. 
Time (min) MilliQ (%) Methanol (%) Acetone (%) Flash tubes Fraction number 
0-6 95 5 0 1-3 F1 
6-12 75 25 0 4-6 F2 
12-18 50 50 0 7-9 F3 
18-24 25 75 0 10-12 F4 
24-36 0 100 0 13-15 F5 
36-42 0 50 50 16-18 F6 
42-54 0 0 100 19-27 F6 
 
4.4.3 Preparation of SNAP columns for flash fractionation 
 
6.5 g of Diaion® HP-20SS column material (adsorbent) was pre-treated by soaking in 75 mL 
methanol for minimum 20 minutes before exchanging with MilliQ water, and packing in a flash 









4.4.4 Stock solution preparation  
 
Materials 
Table 8: Equipment used in stock solution preparation. 
Equipment Equipment identification Supplier 
Dimethyl Sulfoxide D4540 Sigma-Aldrich (St. Louis, MO, USA) 
MilliQ water - Merck KGaA (Germany) 
Heto PowerDry® Freeze Dryer PL9000 Thermo Fisher Scientific  
Büchi Syncore® Polyvap - Büchi (Switzerland) 
Universal Shaker  SM 30 Edmund Buhler GmbH (Germany) 
 
Method 
Subsequently, after pre-fractionation all fractions were dried using Polyvap and stored at -20 
°C until further use. The flash fractions were diluted to 40 mg/mL in dimethyl sulfoxide 
(DMSO) and dissolved using the shaking machine. The DMSO solved fractions were 
transferred into separate cryo tubes and stored at –20 °C. Deep-well plates (DWPs) were 
prepared with all the fractions for bioactivity screening. The fractions were first frozen in the 
DWPs followed by freeze-drying until completely dry. Next, the fractions were dissolved in a 
2.5% (v/v) DMSO solution prepared in autoclaved MilliQ water to a concentration of 1 mg/mL, 
and the plates were stored at -20 °C until further use for bioactivity screening. 
4.5 Bioactivity screening of flash fractions 
 
All fractions were screened for antibacterial and anticancer activity. The bioactivity screening 
of fractions was performed in a class II safety cabinet. The flash fractions were screened for 
antibacterial activity against the bacterial strains S. aureus, E. coli, E. faecalis, P. aeruginosa, 
Streptococcus type B and Methicillin-resistant S. aureus, using one concentration (100 µg/mL) 
in primary screening. The active fractions were re-tested in a secondary secreening using two 
concentrations (50 and 25 µg/mL) to confirm activity and eliminate the possibility of getting 
false positives. The flash fractions were screened for anticancer activity against the human 
melanoma cancer cell line A2058. All fractions were screened in one concentration (100 
µg/mL) to investigate activity. The fractions that showed activity were further analysed using 
preparative RP-HPLC while non-active fractions were excluded from further work. The 




4.5.1 Antibacterial activity screening  
 
Materials 
Table 9: Equipment used for antibacterial activity screening. 
Equipment Equipment identification Supplier 
Brain heart infusion broth (BHI) 53286 Sigma-Aldrich (USA) 
Mueller Hinton broth (MH) 275730 Difco 
Blood agar plates - 
University hospital of North Norway 
(UNN) 
Luria-Bertoni plates - 
University hospital of North Norway 
(UNN) 
Gentamycin A 2712 VWR International S.A.S (France) 
MilliQ Ultrapure water - Merck kGaA (Germany) 
Heated Incubator MIR-262 - Panasonic Healthcare (Japan) 
Incubator Unimax  1010 
Heidolph Instruments GmbH & Co 
(Germany) 
Victor Multilabel Counter photometric 
instrument 
- Perkin Elmer, (Massachusetts, USA) 
Herasafe biological safety cabinet Class II Thermo Fisher Scientific (MA, USA) 
E. coli ATCC® 25922 LGC Standards (UK) 
S. aureus ATCC® 25923 LGC Standards (UK) 
E. faecalis ATCC 29212 LGC Standards (UK) 
P. aeruginosa ATCC 27853 LGC Standards (UK) 
Streptococcus type B  ATCC® 12386 LGC Standards (UK) 
MRSA ATCC® 43330 LGC Standards (UK) 
 
Method 
4.5.1.1 Preparation of the test bacteria 
 
All fractions were screened for antibacterial activity against six human pathogenic bacterial 
strains (Table 10). The test bacteria were taken out from the freezer, where they were stored at 
–80 °C, and kept on ice. The bacterial strains were stroked onto blood agar plates and incubated 
at 37 °C overnight. Afterwards, a scoop of the bacteria from the blood agar plates was 
transmitted into 8 mL growth medium in falcon tubes and incubated overnight at 37 °C. 
Different growth medium was used for cultivation of the six bacterial strains (Table 10). 2 mL 
of the bacterial suspension was transmitted into 25 mL fresh cultivation medium and the 
cultures were incubated under shaking at 37 °C for the time stated in Table 10 to reach 0.5 
McFarland turbidity (1.0 × 108 bacteria/mL). The bacterial solution was diluted 1:1000 in the 









Table 10: The test bacteria used in the antibacterial activity screening, their cultivation medium, incubation time needed to 




Incubation period (hours) Bacterial density (CFU ranges) 
S. aureus MH 2.5  
0.5-3x105 CFU/mL (2500-15000 
CFU/well) 
E. coli  MH 1.5  
0.5-3x105 CFU/mL (2500-15000 
CFU/well) 
E. faecalis BHI 1.5 
0.5-3x105 CFU/mL (2500-15000 
CFU/well) 
P. aeruginosa MH 2.5 
3-7x104 CFU/mL (1500-3500 
CFU/well) 
Streptococcus type B  BHI 1.5  
0.5-3x105 CFU/mL (2500-15000 
CFU/well) 
MRSA BHI 2.5 
0.5-3x105 CFU/mL (2500-15000 
CFU/well) 
 
4.5.1.2 Preparation of the 96-well microtiter plates 
 
Fractions were taken from the test-DWP (see section 4.4.4 ‘’Stock solution preparation’’) and 
diluted with autoclaved MilliQ water to the selected concentrations. All fractions were screened 
at a concentration of 100 µg/mL (in duplicates) in the primary screening. The active fractions 
were re-tested in a secondary screening at 50 and 25 µg/mL (in duplicates). 50 µL of the 
fractions were transferred to 96-well microtiter plates, one plate was used for each bacterial 
strain that was tested. Subsequently, 50 µL of the prepared 1:1000 bacterial solutions were 
added to the fractions. In addition, positive and negative controls for the screening were 
included on the plates. Negative control (N) was added to the first column on the plate and it 
was prepared with 50 µL growth medium and 50 µL autoclaved MilliQ, whereas positive 
control (P) was added to the last column on the plate and it was prepared with 50 µL bacterial 
suspension and 50 µL autoclaved MilliQ. The microtiter plates were incubated for 20-24 hours 









Table 11: Setup for MIC assay. N is negative control. P is positive control.  
 1 2 3 4 5 6 7 8 9 10 11 12 
A N 1 1 9 9 17 17 25 25 33 33 P 
B N 2 2 10 10 18 18 26 26 34 34 P 
C N 3 3 11 11 19 19 27 27 35 35 P 
D N 4 4 12 12 20 20 28 28 36 36 P 
E N 5 5 13 13 21 21 29 29 37 37 P 
F N 6 6 14 14 22 22 30 30 38 38 P 
G N 7 7 15 15 23 23 31 31 39 39 P 
H N 8 8 16 16 24 24 32 32 40 40 P 
 
4.5.1.3 Gentamycin control   
 
For controlling and validating the stability of the bacterial strain a gentamycin control of the 
setup was used. The control was performed in the following concentrations: 16 µg/mL, 10 
µg/mL, 8 µg/mL, 4 µg/mL, 2 µg/mL, 1 µg/mL, 0.5 µg/mL, 0.25 µg/mL, 0.13 µg/mL, 0.06 
µg/mL, 0.03 µg/mL and 0.02 µg/mL, to determine the minimum inhibitory concentration of 
gentamycin for the test bacteria. 50 µL gentamycin control was transferred to 50 µL bacterial 
solution in a 96-well microtiter plate and the plate was incubated at 37 °C overnight. The MIC 
values were determined by visual inspection of growth inhibition. The screening had to be run 
again if the MIC values (Table 12) for gentamycin were beyond the reference values by more 
than one titer step.  
Table 12: Reference MIC values for the test bacteria used in the antibacterial screening. 
Test bacteria Reference MIC values 
for gentamycin (µg/mL) 
S. aureus 0.06  
E. coli 0.13 
E. faecalis 8 
P. aeruginosa 0.25 
Streptococcus type B 4 
MRSA 0.015 
 
4.5.1.4 Control of colony forming unit 
 
After incubation of 1.5 hours, the bacterial solution was diluted 100 000 and 1 000 000 times 
in 0.9% sodium chloride solution. Furthermore, 100 µL of the diluted suspensions were stroked 
out in two parallels on Luria-Bertoni plates and incubated at 37 °C overnight. Afterwards, the 
quantity of colonies was counted, and the bacterial density (CFU) was determined and 
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compared to the standard CFU ranges (Table 10). The bacterial growth was deemed normal if 
the calculated CFU were within the range of the standard CFU ranges.  
4.5.1.5 Reading of plates and evaluation of results 
 
The microtiter plates were observed visually for growth inhibition after incubation for 20-24 
hours. Subsequently, the photometric instrument was used to measure the absorbance of the 
microtiter plates at 600 nm (Abs600). The software WorkOut 2.5 was utilised to process the 
results. The fractions were characterised either as active, questionable or inactive based on the 
Abs600 values.  
• Active < 0.05 
• Questionable 0.05-0.09 
• Inactive > 0.09 
Fractions considered active or questionable were re-tested in the secondary screening.  
4.5.2 Anticancer activity screening 
 
Materials 








Roswell Park Meomorial Institue 
medium (RPMI-1640) 
FG 1383 Merck KGaA (Germany) 




LGC Standards (UK) 
CellTiter 96® Aqueous One Solution 
Reagent (AQOS) 
G358B Promega (Wisconsin, USA) 
Gentamycin (10 mg/mL) A 2712 Merck KGaA (Germany) 
L-Alanyl-L-Glutamine (200 nM)  K 0302 Merck KGaA, Germany 
TritonTM X-100 T8787 Sigma-Aldrich (Missouri, USA) 
Dulbecco’s Modified Eagle Medium  
(D-MEM) 
32430027 
Thermo Fisher Scientific (Massachusetts, 
USA) 
Sanyo CO2 Incubator MCO-18AIC - Panasonic Biomedical (Japan) 
DTX Multimode Detector 880 Beckman Coulter (California, USA) 
Herasafe biological safety cabinet Class II 




The cells were seeded in a 96-well microtiter plate in D-MEM medium with 10% FBS,  
gentamycin (10 µg/mL) and 1% L-Alanyl-L-glutamine, at a concentration of 2000 cells/wells. 
The plates were incubated at 37 °C with 5% CO2 for 24 hours. After incubation, the medium 
was replaced with RPMI-1640 medium with 10% FBS, gentamycin (10 µg/mL) and 1% L-
Alanyl-L-glutamine. Fractions were taken from the test-DWP (see section 4.4.4 ‘’Stock 
Solution Preparation’’) and diluted in RPMI medium to the chosen concentration. 100 µL of 
the fractions were added to the cells in triplicates at a concentration of 100 µg/mL (Table 14). 
Negative controls (N) made with RPMI-1640 medium containing 10% FBS and positive 
controls (P) made with 1% triton were included in the plates as well. The plates were further 
incubated for 72 hours at 37 °C with 5% CO2. Afterwards, 10 µL Aqueous One Solution was 
added to each well, and the plates were incubated for 1 additional hour.  
Table 14: Setup for cancer assay. Two sets of 8 fractions in triplicates were seeded in each plate. ‘’a’’ indicates the first set of 
fractions. ‘’b’’ indicates the second set of fractions. (N) indicates negative control. (P) indicates positive control. The grey 
areas indicate wells containing only medium.  
 1 2 3 4 5 6 7 8 9 10 11 12 
A             
B  1a 2a 3a 4a 5a 6a 7a 8a (N)   
C  1a 2a 3a 4a 5a 6a 7a 8a (N)   
D  1a 2a 3a 4a 5a 6a 7a 8a (N)   
E  1b 2b 3b 4b 5b 6b 7b 8b (N)   
F  1b 2b 3b 4b 5b 6b 7b 8b   (P) 
G  1b 2b 3b 4b 5b 6b 7b 8b   (P) 
H            (P) 
 
4.5.2.1 Reading of plates and evaluation of results 
 
The absorbance was recorded at 485 nm using the DTX 880 Multimode Detector, and cell 
survival calculated using equation 1. The fractions were characterised either as active, 
questionable or inactive based on the cell survival.  




Equation 1: Calculation of cell survival (%). At is the average absorbance value measured in wells with fractions, 
Ab is the average absorbance value measured in wells with positive control, and Ac is the average absorbance 
measured in wells with negative control.  
• Active < 50% cell survival  
• Questionable 50-60% cell survival  
• Inactive > 60% cell survival  
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4.6 Re-fractionation of active flash fractions 
 
Materials  




Acetonitrile  75-05-8 Merck KGaA (Germany) 
MilliQ - Merck KGaA (Germany) 
Formic acid 64-18-6 Sigma-Aldrich (St. Louis, MO, USA) 
Methanol  20864 VWR International S.A.S (France) 
Preparative HPLC-MS system - Waters (MA, USA) 
HPLC pump 515 Waters (MA, USA) 
Controller 600 Waters (MA, USA) 
Mass Detector 3100 Waters (MA, USA) 
Photo Diode Array Detector 2996 Waters (MA, USA) 
Sample Manager (Fraction controller) 2767 Waters (MA, USA) 
Xterra® Shield RP 18 OBDTM prep 
column 
- Waters (MA, USA) 
Software: MassLynx  Version 4.1 Waters (MA, USA) 
Express SpeedVac Concentrator SC250 Thermo Fisher Scientific (MA, USA) 




The re-fractionation of the active flash fractions was done on a preparative HPLC-MS system. 
The system was composed of a HPLC-pump, an in-line-solvent degasser, a fraction-collector 
and injector, a UV/Vis-flow-spectrometer and a mass detector. The HPLC-MS instrument was 
tuned and optimised using the software MassLynx version 4.1. The source temperature was 120 
°C, the desolvation temperature was 300 °C and the desolvation gas flow rate was set to 650 
L/hr. The capillary and cone voltages were 15 V and 40 V, respectively. HPLC separations 
were performed on a 125 Å, 10 µm, 10 mm × 300 mm X-Terra Shield C18 column at a flow 
rate of 6 mL/min. Re-fractionation was arranged to collect one fraction per minute, with a total 
of 40 fractions collected per analysis and 6 mL in each fraction, with a gradient of two mobile 
phases: 
• Mobile phase A: MilliQ H2O with 0.1% (v/v) formic acid  
• Mobile phase B: Acetonitrile with 0.1% (v/v) formic acid  
Different mobile phase gradients were used for the flash fractions to obtain efficient separation 
of the compounds in each of them. The gradient used for the flash fractions labelled ‘X0845_05’ 
and ‘X0811B_05’ was 25% B to 100% B in 32 minutes, while the gradient used for the flash 
fraction labelled ‘X0834B_05’ was 15% B to 100% B in 32 minutes. Before injection, the 
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fractions were diluted with 80% methanol to reduce their viscosity. 880 µL of the flash fraction 
labelled ‘X0845_05’ was injected, while 750 µL of the flash fractions labelled ‘X0811B_05’ 
and ‘X0834B_05’ were injected. The injection volume was selected by a ‘’trial-and-error’’ 
approach. The fractions obtained will be referred to as subfractions further in the thesis.  
4.6.1 Treatment of subfractions after re-fractionation 
 
After re-fractionation, each subfraction was split between three DWPs for bioactivity screening. 
Each fraction contained 6 mL, so 2 mL of each fraction was transferred to each DWP using an 
electric 1-10 mL pipette with the stepper settings 3*2 mL. Next, the DWPs were vacuum 
centrifuged in the SpeedVac for 3 hours to remove organic solvents. The plates were placed in 
the freezer at -80 °C overnight, before they were freeze-dried for 24 hours to remove the 
remaining water. The subfractions were dissolved in 300 µL 1% (v/v) DMSO aq., and the plates 
were stored at -20 °C until further use for bioactivity screening.  
4.7 Bioactivity screening of subfractions 
 
Antibacterial and anticancer activity screening were performed as described in section 4.5.1 
‘’Antibacterial activity screening’’ and section 4.5.2 ‘’Anticancer activity screening’’, 
respectively. However, the subfractions were only screened for antibacterial activity against the 
bacterial strains E. coli and Streptococcus type B. In addition, only fractions from the bacterial 
strains M09W202 and M10B807 were screened for anticancer activity.  
4.8 Dereplication of active subfractions from bioactivity screening 
 
Materials  
Table 16: Equipment used in the dereplication process.  
Equipment Equipment identification Supplier 
HPLC glass vials - Waters (Milford, MA, USA) 
VION® IMS QToF - Waters (Milford, MA, USA) 
Acquity UPLC Column Manager - Waters (Milford, MA, USA) 
Acquity UPLC PDA Detector - Waters (Milford, MA, USA) 
Acquity UPLC BEH C18 Column - Waters (Milford, MA, USA) 
Software: UNIFI  Version 1.8.2 Waters (Milford, MA, USA) 
MilliQ water - Merck KGaA (Germany) 
Formic acid  64-18-6 Sigma-Aldrich (St. Louis, MO, USA) 
Acetonitrile 75-05-8 Merck KGaA (Germany) 





The subfractions considered active in the bioactivity screening were analysed using UHPLC-
QToF-MS. 50 µl of the subfractions were transferred to HPLC glass vials and injected in the 
UHPLC system. The flow rate was maintained at 0.450 mL min-1 and a volume of 5 µL of each 
fraction was injected. Separation was obtained on a C18 column (2.1 × 100 mm, 1.7 µm) with 
a linear gradient consisting of MilliQ water (A) and acetonitrile (B), both containing 0.1% (v/v) 
formic acid, starting at 10% B and increased to 100% B in 12 minutes. The samples were run 
in both, positive and negative ion mode (ESI- and ESI+), in separate runs. N2 was used as the 
desolvation gas. The desolvation temperature was 450 °C, the flow rate was 800 L/h and the 
source temperature was 100 °C. The capillary and cone voltages were 0.80 kV and 40 V, 
respectively. The data were collected for each test sample across a mass range of 50-2000 m/z 
with a scan time of 0.2 seconds. 
 
The active subfractions were compared to the inactive ones, in order to identify compounds 
found particularly, or in a significantly higher concentration in the active subfractions. This was 
done in an attempt to determine possible compounds responsible for the observed activity. The 
software Waters UNIFI version 1.8.2 was utilised to calculate a possible elemental composition 
for these compounds, based on accurate masses and the isotopic pattern of the compounds. 
Furthermore, the calculated elemental compositions were used to search databases via 
ChemSpider, mainly Marine Drugs, Marinlit, Natural Product Updates, Nature Chemical 
Biology and Nature Chemistry, to assess whether the compounds were new or previously 













4.9 Upscaling and purification of possible bioactive compounds  
 
Materials  





Acetonitrile  75-05-8 Merck KGaA (Germany) 
MilliQ - Merck KGaA (Germany) 
Formic acid 64-18-6 Sigma-Aldrich (St. Louis, MO, USA) 
Methanol  20864 VWR International S.A.S (France) 
preparative HPLC-MS system - Waters (MA, USA) 
HPLC pump 515 Waters (MA, USA) 
Controller 600 Waters (MA, USA) 
Mass Detector 3100 Waters (MA, USA) 
Photo Diode Array Detector 2996 Waters (MA, USA) 
Sample Manager (Fraction controller) 2767 Waters (MA, USA) 
X-Terra® Shield RP 18 OBDTM prep column - Waters (MA, USA) 
XSelectTM CSHTM Fluoro-Phenyl prep column - Waters (MA, USA) 
SunFireTM Shield RP 18 OBDTM prep column  - Waters (MA, USA) 
SpeedVac Concentrator SC250 Thermo Fischer Scientific (MA, USA) 
 
Method 
The purification of the compounds of interest was carried out by utilising the same HPLC-MS 
equipment, software and mobile phases as described in section 4.6 ‘’Re-fractionation of active 
flash fractions’’. The purification was run in two rounds in order to obtain material of sufficient 
purity for further investigation. Various columns were used at a flow rate of 6 mL/min in an 
attempt to isolate and purify these compounds (Table 18). The injection volume was selected 
by a ‘’trial-and-error’’ approach, varying between 100-400 µL for the isolated compounds. The 
mobile phase gradients used for purification of the compounds are listed in Table 18, and they 
were selected based on results from previous runs.  
The isolated compounds were collected in fractions using time or mass triggered fractionation 
and dried by vacuum centrifugation in the SpeedVac. They were resuspended in 400 µL 
methanol and 100 µL DMSO for the second purification round. In the second purification 
round, the compounds were collected in fractions using mass triggered fractionation. After 
purification, the compounds were dried in the SpeedVac and dissolved in 1% (v/v) DMSO aq. 





Table 18: Column, gradient and run-time used for the first and the second isolation rounds of the different compounds.  
Compound Separation round Column Gradient (%) ACN Time (min) 
TS-7-mix First X-Terra 15-100 32.00 
TS-7-317 First X-Terra/SunFire 15-100/20-100 32.00/32.00 
TS-7-281 
First X-Terra/SunFire 15-100/20-100 32.00/32.00 
Second Fluoro-phenyl 20-100 15.00 
TS-7-558 First Fluoro-phenyl 20-100 15.00 
TS-7-rt10-13 First Fluoro-phenyl 20-100 15.00 
TS-19-227 
First X-Terra/SunFire 15-100/20-100 32.00/32.00 
Second Fluoro-phenyl 20-100 15.00 
TS-25-398 
First X-Terra 15-100 32.00 
Second Fluoro-phenyl 50-100 15.00 
TS-25-386 
First X-Terra 15-100 32.00 
Second Fluoro-phenyl 50-100 15.00 
TS-4-652 
First X-Terra 50-100 15.00 
Second Fluoro-phenyl 10-40 15.00 
TS-4-265 First Fluoro-phenyl 10-40 15.00 
AM-23-404 
First SunFire 50-100 15.00 
Second Fluoro-phenyl 50-100 15.00 
AM-24-404 
First SunFire 50-100 15.00 
Second Fluoro-phenyl 50-100 15.00 
AM-25-418 
First SunFire 50-100 15.00 
Second Fluoro-phenyl 50-100 15.00 
/, indicates that the compounds were isolated in two rounds using different columns and elution gradients. The 
compounds are named based on the bacterial strain they are isolated from, the subfractions in which they were 
eluting and their m/z values or retention time. TS indicates that the compounds are isolated from Thalassospira. 
AM indicates that the compounds are isolated from Alteromonas.  
4.10 Bioactivity screening of the isolated compounds 
 
The isolated compounds considered responsible for the observed activity were screened for 
antibacterial activity as described previously in section 4.5.1 ‘’Antibacterial activity screening’’ 
in order to confirm their activity. The compounds were screened for antibacterial activity 
against the bacterial strain Streptococcus type B in three different concentrations (50, 10 and 5 
µg/mL). However, the compounds TS-7-281, TS-7-317, TS-7-558, and TS-7-rt10-13 were only 
tested in 50 µg/mL, and they were also screened for anticancer activity against the cell line 
A2058 as described in section 4.5.2 ‘’Anticancer activity screening’’ in 50 µg/mL. Moreover, 
the compounds AM-23-404, AM-24-404 and AM-25-418 were submitted to NMR analaysis 






4. 11 Structure elucidation of target compounds by NMR 
 
This part of the project was performed by Johan Isaksson at the Department of Chemistry at 
UiT The Arctic University of Norway.  
All NMR spectra were acquired on a Bruker Avance III HD spectrometer equipped with an 
inverse detected TCI probe with cryogenic enhancement on 1H, 2H and 13C, operating at 
599.90 MHz and 150.86 MHz for 1H and 13C, respectively. Samples were prepared in DMSO-
d6 and methanol-d4, and recorded at 298 K. All experiments were acquired using standard pulse 
sequences for Proton, Presat, Carbon, DQFCOSY, ECOSY, HSQC (bip), HMBC (bip), H2BC 
(bip), HSQCTOCSY (mlev), TOCSY (clean mlev), NOESY and ROESY (adiabatic) in 
Topspin 3.5pl7, using gradient selection where applicable, and processed in Mnova 12.0.0. 
Spectra were referenced on the residual solvent peak of methanol-d4 (δH = 3.31 and δC = 49.00) 
















5.0 Results  
 
5.1 Extraction of the bacterial cultures  
 
The secreted secondary metabolites produced by the bacteria were harvested from the culture 
media using Diaion® HP-20 resin and extracted with methanol, and the extracts were dried 
under reduced pressure for further investigation. The weight of the crude extracts obtained from 
the bacterial strains AM, PM and TS were 6.05 g, 18.33 g and 17.75 g, respectively.  
5.2 Pre-fractionation of the extracts  
 
The crude extracts from the bacterial strains were pre-fractionated into six flash fractions, where 
only flash fraction 5 was used further in the thesis as the other fractions did not display any 
activity. The weight of flash fraction 5 obtained from the bacterial strains AM, PM and TS were 
34 mg, 4081.7 mg and 380.8 mg, respectively.  
5.3 Bioactivity screening of flash fractions 
 
Antibacterial activity was first tested in one concentration (100 µg/mL). Fraction 5 was found 
to be active, and it was therefore re-tested at final concentrations of 50 µg/mL and 25 µg/mL. 
Fraction 5 from the extracts of PM and AM showed inhibitory activity against the bacterial 
strains E. faecalis and Streptococcus type B (Fig. 12, 13 and 14). However, fraction 5 of PM 
had only slight activity (questionable) against the bacterial strain E. faecalis and no activity was 
observed against this strain at the lowest tested concentration (Fig. 14). Fraction 5 from the 
extract of AM also showed activity against MRSA at the highest tested concentrations (Fig. 12 
and 13). As for fraction 5 from the extract of TS, slight activity (questionable) against the 
bacterial strain MRSA was observed at concentrations of 100 and 50 µg/mL (Fig. 12 and 13). 
Questionable fractions were treated as active and were further analysed. None of the fractions 
displayed activity against Gram negative test strains (results not shown). Furthermore, only 
fraction 5 of the extracts of PM and AM displayed anticancer activity (Fig. 15). Hence, fraction 
5 from the extracts of all three bacterial strains were further investigated for antibacterial 
activity, whereas only fraction 5 of the extracts of the bacterial strains PM and AM were further 
investigated for anticancer activity. No antibiotic or anticancer activity was observed for any of 




Figure 12: The antibacterial activity of flash Fractions 1-6 from the extracts of AM (M09W202), PM (M10B807) and TS 
(M10B738) were tested in a growth inhibition assay. Results from the screening against gram negative strains are not 
shown. The test concentration was 100 µg/mL. Antibacterial assay: Active, Abs600 nm < 0.05; Questionable, Abs600 nm 
0.05-0.09; Inactive, Abs600 nm > 0.09.   
 
Figure 13: The antibacterial activity of flash Fraction 5 from the extracts of AM (M09W202), PM (M10B807) and TS 
(M10B738) was tested in a growth inhibition assay. The test concentration was 50 µg/mL. Antibacterial assay: Active, 





























Figure 14: The antibacterial activity of flash Fraction 5 from the extracts of AM (M09W202), PM (M10B807) and TS 
(M10B738) was tested in a growth inhibition assay. The test concentration was 25 µg/mL. Antibacterial assay: Active, 




Figure 15: The anticancer activity of flash Fractions 1-6  from the extracts of AM (M09W202), PM (M10B807) and TS 
(M10B738). Anticancer activity of the fractions were estimated with a cell viability assay. The tested concentration was 100 
µg/mL. Viability assay: Active, < 50% cell survival; Inactive, > 50% cell survival.  
5.4 Re-fractionation of active flash fractions 
 
It was not possible to assign the bioactivity observed in flash fractions with sufficient certainty 
to any known compound in the dereplication process. Thus, the active flash fractions were 
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attempt to identify the compounds responsible for activity via bioassay guided purification. The 
resulting BPI chromatograms can be seen in Fig. 16.  
 
Figure 16: BPI chromatograms (ESI+) from the re-fractionation of flash fraction 5 from the bacterial strains TS (top), PM 
(middle) and AM (bottom), with prep HPLC-MS. The fractions were injected onto a Waters X-Terra® Prep RP18 (10 µm 
10x300 mm) column. A mobile phase gradient of MilliQ water and Acetonitrile, both with 0.1% (v/v) FA, was used with a 
flow rate of 6 mL/min. 40 subfractions were collected from each flash fraction.  
5.5 Bioactivity screening of subfractions 
 
The subfractions were screened for antibacterial and anticancer activity in order to select which 
fractions to focus on and which to terminate.  
5.5.1 Antibacterial activity screening of subfractions 
 
The 40 subfractions obtained by preparative HPLC were tested for antibacterial activity 
against the two bacterial strains E. coli and Streptococcus type B. The subfractions were first 
tested diluted in 300 µL 1% (v/v) DMSO aq., showing a high number of active fractions 
occuring in a sequence, particularly against the bacterial strain Streptococcus type B (results 
not shown). The high activity was suspected to be caused by organic compounds not of 
interest or it could be that the same active compounds were spread over several subfractions. 
Hence, the subfractions in each DWP were tested diluted 1:10 in 1% (v/v) DMSO to 
investigate if the results were reproducible, and as high dilution may result in detection of 
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potent active compounds. Therefore, we took out 100 µL of the dissolved fractions and 
diluted it with 900 µL 1% (v/v) DMSO in water to a 1:10 dilution in a new DWP for re-
testing. The 1:10 dilution has resulted in much less activity. The subfractions 23-27 from the 
extract of AM were active against the bacterial strain Streptococcus type B. The subfractions 
19-32 from the extract of PM showed activity against the same test strain. The subfractions 3-
11 and 25-27 from the extract of TS displayed activity against the same test strain as well. 
None of the fractions displayed activity against E. coli (results not shown).  
5.5.2 Anticancer activity screening of subfractions 
 
The subfractions from extracts of PM and AM were screened for anticancer activity diluted 
first in 300 µL 1% (v/v) DMSO, resulting in observed activity in the subfractions 24-31 from 
the extract of PM, and no activity for any of the subfractions from the extract of AM. The 
subfractions were further diluted 1:10 in 1% (v/v) DMSO as described under 5.5.1 
‘’Antibacterial activity screening of subfractions’’ and screened for anticancer activity again, 
resulting in no activity for any of the subfractions neither from PM or AM (results not 
shown).  
5.6 Dereplication of active subfractions from bioactivity screening 
 
Several compounds detected in the active subfractions could be responsible for the observed 
activity. However, some of the compounds were highlighted as most likely active as they were 
exclusively present, or present in a considerably higher concentration in active fractions 
compared to inactive fractions and were thus, selected for further investigation. To identify the 
compounds that possibly caused the observed antibiotic activity in the bioassay, the active 
subfractions in which these compounds were eluting, were analysed by HR-MS. Potentially 
active compounds were isolated and tested for bioactivity to be certain whether they were 
responsible for the observed activity or not. The MS chromatogram of some fractions 
considered active, showed only background noise and no signals were observed neither in 
positive or negative ESI mode, such as the fractions AM-26 and 27, PM-30 and TS-8 to 11. 
Compounds were however detected in the UV/Vis detector. These were excluded from further 
study as they were suspected of being lipids, fatty acids and other compounds not of interest, 
according to the experience of Marbio. The subfractions selected for dereplication with HR-
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MS based on the results from antibacterial activity screening and the comparison of active 
fractions with inactive ones were:  
• TS-3, TS-4, TS-7, TS-25, TS-26 and TS-27 
• AM-23, AM-24 and AM-25 
• PM-19, PM-25, PM-27 and PM-29 
5.6.1 Compounds selected for isolation from the bacterial strain TS 
 
Subfraction 3  
No compounds of interest were found in this subfraction as metabolites with unspecific effects 
were suspected to be responsible for the observed bioactivity and as a result, the subfraction 
was excluded from further work. Moreover, several of the compounds present in this fraction 
were found to be growth media components.  
Subfraction 4 
The mass signal m/z 652.6 ([M+H]+) detected in the active subfraction 4 from the bacterial 
strain TS was believed to be responsible for the observed activity in this fraction, as it was 
particularly present in the fraction in relatively high concentration. The calculated elemental 
composition for this compound was C26H73N19, which gave several hits in database searches. 
Together with another compound with m/z 265.2 it was identified as a growth media component 
and both were excluded from further work. 
Subfraction 7 
Several compounds were candidates for the observed activity in subfraction TS-7. Thus, all the 
compounds of interest were isolated in a fraction named TS-7-mix for bioactivity screening in 
order to investigative whether some of them were active. The compounds most likely 
responsible for the observed activity were isolated and re-tested for activity as pure compounds 
for bioactivity confirmation. This fraction was compared to that of the growth medium used in 
cultivation of the bacterial strain TS in order to avoid selecting growth media components for 
isolation. Two compounds with m/z 281.6 and 317.4 were suspected of being responsible for 
the observed bioactivity based on the results from dereplication and comparison of this fraction 
with that of the growth medium. No elemental composition was calculated for these compounds 
in HR-MS, so they were selected for isolation and characterisation by NMR analysis, since they 




In flash fraction 5 from the extract of TS, a compound with m/z 227.01 ([M+H]+) (Fig. 17) of 
interest was detected, and despite that the subfraction TS-19 in which it was eluting did not 
display any antibacterial activity, it was decided to isolate this compound for structure 
elucidation due to interesting chemical properties, as well as it potentially being active in other 
assays. The mass spectrum of this compound can be seen in Fig. 17-right, showing a pattern 
with three signals, m/z 227, 229 and 231, with a 9:6:1 ratio and separated by two mass units. 
This isotope pattern indicates that the compound contains two Cl atoms in its structure. The 
elemental composition was calculated to be C10H8N2Cl2, and it was suggested to be an 
aminopyrrolnitrin in databases, several other hits were however given indicating uncertainty 
about its identity. The compound was therefore isolated for further investigation.  
 
Figure 17: Left) HR-MS BPI chromatogram of the active flash fraction 5, in positive ESI mode. The fraction was injected into a 
Waters Aquity UPLC® (2.1x100 mm, 1.7 µm) column, and a mobile phase gradient of MilliQ water with 0.1% (v/v) FA and 
Acetonitrile with 0.1% (v/v) FA was used with a flow rate of 0.45 ml/min. Right) Mass spectrum for the compound TS-19-227 







Two signals with m/z 398.3 ([M+H]+) and 386.3 ([M+H]+) were detected in the active 
subfraction 25 from the extract of TS (Fig. 18). These compounds were suspected to possibly 
be responsible for the observed activity in this fraction, as they were exclusively present in the 
fraction in high concentrations and were not observed in any of the inactive fractions. The mass 
spectra of these compounds are given in Fig. 18-right. Their calculated elemental compositions 
were C22H39NO5 and C21H39NO5, respectively. These formulas gave no hits in the most 
commonly used databases. Hence, these compounds were submitted to isolation and 
purification using preparative HPLC-MS for further investigation, and they were named TS-
25-398 and TS-25-386, respectively.  
 
Figure 18: Left) HR-MS BPI chromatogram of the active fraction TS-25, in positive ESI mode. The fraction was injected into a 
Waters Aquity UPLC® (2.1x100 mm, 1.7 µm) column, and a mobile phase gradient of MilliQ water with 0.1% (v/v) FA and 
Acetonitrile with 0.1% (v/v) FA was used with a flow rate of 0.45 ml/min. Right) Mass spectrum for the compounds 398.3 






Subfractions 26-27  
No compounds of interest were found in these subfractions as lipids were suspected to be 
responsible for the observed bioactivity, and as a result the subfractions were excluded from 
further work. Moreover, several of the compounds present in these fractions were found to be 
growth media components.  
5.6.2 Compounds selected for isolation from the bacterial strain PM 
 
In the active subfractions PM-19 and PM-25, two peaks with m/z 553.3369 ([M+Na]+) and 
555.3502 ([M+Na]+) were detected. Their calculated elemental compositions were, C28H50O9 
and C28H52O9, respectively, giving several hits in database searches. Their retention times, 
masses and elemental compositions were consistent with Rhamnolipids (RLs), which have been 
previously isolated from a different bacterial strain at Marbio, including a Pseudomonas species 
(94). RLs have been reported to exhibit various bioactivities including antimicrobial and 
anticancer, they were thus suggested to be responsible for the observed activity. Further work 
on these fractions was as a consequence of this terminated. Moreover, a peak with m/z 381.2611 
([M+Na]+) was detected in the active subfractions PM-27 and PM-29. The calculated elemental 
composition of this compound was C20H38O5, and it was identified as a RL based on previous 
findings. This compound was hence believed to be responsible for the observed activity. As a 
result, no compounds were isolated from this bacterial strain. 
5.6.3 Compounds selected for isolation from the bacterial strain AM 
 
In the active subfractions AM-23 and AM-24, two peaks with m/z 555.3499 ([M+Na]+) and 
555.3508 ([M+Na]+) were detected (marked with black arrows in Fig. 19). The calculated 
elemental composition of both compounds was C28H52O9, indicating RLs, which is consistent 
with previous findings. Another RL with m/z 555.3494 ([M+Na]+) was detected in the active 
subfraction AM-25 (marked with a black arrow in Fig. 19) and its elemental composition was 
calculated to be the same as the two other RLs. The RL was however present in lower quantities 
in this subfraction compared to the two other subfractions, and a dominating peak with m/z 
418.2946 (marked with a red arrow in Fig. 19) was suspected to be the compound that might 
cause the observed antibacterial activity, and thus selected for isolation and bioactivity 
confirmation. The same compound was also present in the active subfraction AM-24. The 
elemental composition of this compound was calculated to be C25H39O4N, resulting in no hits 
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in the most common databases. In addition, two compounds with m/z 404.2788 (marked with 
blue arrows in Fig. 19) eluting in the active subfractions 23 and 24 were selected for isolation, 
since they were suspected to be isomers based on their different retention times and they might 
be bioactive. The calculated elemental composition of these compounds was C24H37O4N, giving 
no hits in the most common databases.  
 
Figure 19: HR-MS BPI chromatogram of the active fraction subfractions AM-23, AM-24 and AM-25, in positive ESI mode. The 
fraction was injected into a Waters Aquity UPLC® (2.1x100 mm, 1.7 µm) column, and a mobile phase gradient of MilliQ 
water and Acetonitrile, both with 0.1% (v/v) FA, was used with a flow rate of 0.45 ml/min. 
5.7 Preparative HPLC-MS isolation of target compounds  
 
Target compounds were isolated from the bacterial strains using preparative HPLC-MS. The 
compounds selected for isolation were either suspected of being responsible for the observed 
bioactivity within the subfractions or had interesting chemical properties, such as halogenated 
compounds and isomers. The isolated compounds are summarised in Table 18, and Table 25 
gives an overview of isolated compounds that are selected for further study.  
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5.7.1 Isolation of compounds from the bacterial strain TS 
 
Preparative HPLC-MS purification was performed on flash fraction 5 from the extract of TS in 
order to isolate the target compounds in the active subfractions. The column X-Terra® Shield 
RP 18 was selected for the first round of HPLC separation and the fractions were collected by 
time triggered fractionation. The compounds from the bacterial strain TS selected for isolation 
based on the results from the antibacterial activity screening and dereplication, and the weight 
of the dried fractions after the first isolation are listed in Table 19. The BPI chromatogram from 
this isolation can be seen in Fig. 20.  
Table 19: Isolated compounds from the bacterial strain TS and their dry weight after first purification.  
Fraction Weight (mg) 
1. TS-25-398 and TS-25-386 1.6 
2. TS-7-mix 29.1 
3. TS-19-227 1.1 
4. TS-4-652 3.3 
 
 
Figure 20: BPI chromatogram (ESI+) from the first round of isolation of compounds considered responsible for the observed 
activity in MIC-assay from flash fraction 5 of the bacterial strain TS. The compounds were separated using a RP 18 column 
with an elution gradient of MilliQ water and ACN, both containing 0.1% (v/v) FA, and a flow rate of 6 mL/min (15% B to 
100% B in 32 minutes). The fractions were collected by time triggered fractionation.  
The fractions were further purified in a second round of preparative HPLC-MS in order to 
remove remaining impurities from the compounds. Purification was carried out using the 
fluoro-phenyl column and the fractions were collected by mass triggered fractionation. Fraction 
TS-4-652 contained a compound with m/z 265.2 (named TS-4-265) that was selected for further 
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purification from the first round of HPLC separation. The weight of the dried fractions is listed 
in Table 20, and the BPI chromatogram from this isolation can be seen in Fig. 21.  
Table 20: Isolated compounds from the bacterial strain TS and their dry weight after second purification. 






*indicates that they were excluded from further work 
 
Figure 21: BPI chromatogram (ESI+) from the second purification of compounds considered responsible for the observed 
activity in MIC-assay from flash fraction 5 of the bacterial strain TS. The compounds were separated using a fluoro-phenyl 
column with an elution gradient of MilliQ water and ACN, both containing 0.1% (v/v) FA, and a flow rate of 6 mL/min. The 
fractions were collected by mass triggered fractionation.  
The compounds TS-7-317 and TS-7-281 were isolated in one and two rounds of HPLC 
separation, respectively. These compounds were isolated from the fraction TS-7-mix as well as 
the flash fraction 5 using different columns and elution gradients in the first round of isolation 
(Table 18). However, the results of isolation from the fraction TS-7-mix is not shown in the 
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thesis since it follows the same principle as flash fraction 5 (Fig. 22). In the first round of 
isolation, the column Sunfire Shield RP 18 OBDTM was selected. The compound TS-7-317 was 
collected using time triggered fractionation, whereas the compound TS-7-281 was collected 
using mass triggered fractionation. Additionally, more of the compound TS-19-227 was 
isolated, as it was required for structure elucidation. The weight of the dried fractions is listed 
in Table 21, and the BPI chromatogram from this isolation can be seen in Fig. 22.  
Table 21: Isolated compounds from the bacterial strain TS and their dry weight after first purification. 
Fraction Weight (mg) 
1. TS-7-281 6.6 
2. TS-7-317 5.6 
3. TS-19-227 1.4 
 
 
Figure 22: BPI chromatogram (ESI+) from the first round of isolation of compounds considered responsible for the observed 
activity in MIC-assay of the fraction TS-7-mix and the compound TS-19-227. The compounds were isolated from flash 
fraction 5, using a RP 18 column with an elution gradient of MilliQ water and acetonitrile, both containing 0.1% (v/v) FA, and 
a flow rate of 6 mL/min (20% B to 100% B in 32 minutes). The fractions 1 and 3 were collected by mass triggered 
fractionation while the fraction 2 was collected by time triggered fractionation.  
The fractions TS-7-281 and TS-19-227 were further purified in a second round of preparative 
HPLC-MS to obtain compounds of sufficient purity for NMR analysis. The fraction TS-7-281 
contained a compound with m/z 558.5 (named TS-7-558) and some other compounds eluting 
from 10 to 13 minutes (named TS-7-rt10-13), which were selected for further purification from 
the first round of HPLC separation. To remove impurities from these fractions, a gradient 
elution of 20% B to 100% in 15 minutes on the fluoro-phenyl column was used. The fractions 
TS-7-281, TS-7-558 and TS-19-227 were collected using mass triggered fractionation, while 
the fraction TS-7-rt10-13 was collected using time triggered fractionation. The weight of the 
dried fractions is listed in Table 22, and the BPI chromatograms from these separations can be 
seen in Fig. 23.  
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Table 22: Isolated compounds from the bacterial strain TS and their dry weight after second purification. 







Figure 23: BPI chromatogram (ESI+) from the second purification of compounds considered responsible for the observed 
activity in MIC-assay. The compounds were separated using a fluoro-phenyl column with an elution gradient of MilliQ water 
and acetonitrile, both containing 0.1% (v/v) FA, and a flow rate of 6 mL/min (20% B to 100% B in 15 minutes). The fractions 
were collected by mass triggered fractionation while the fraction 2 was collected by time triggered fractionation.  
5.7.2 Isolation of compounds from the bacterial strain AM 
 
Three compounds with m/z 418.5, 404.5 and 404.5 were selected for isolation from the flash 
fraction 5 of the bacterial strain AM. The two compounds with same masses were eluting in 
both, subfractions 23 and 24 at different times, indicating it could be two compounds with 
different molecular structures (isomers). They were therefore isolated separately based on their 
retention times, and are named AM-23-404 and AM-24-404, respectively, in the thesis. The 
first isolation round was carried out using the column Sunfire Shield RP 18 OBDTM and the 
fractions were collected by mass triggered fractionation. The fractions were dried in the 
SpeedVac after the first round of isolation and prepared in the mobile phase gradient in which 
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they were eluting for the second round of isolation. The weight of the dried fractions is shown 
in Table 23, and the BPI chromatogram from this separation can be seen in Fig. 24. 
Table 23: Isolated compounds from the bacterial strain AM and their dry weight after first purification. 
Fraction Weight (mg) 
1. AM-23-404 2.4 
2. AM-24-404 1.6 
3. AM-25-418 1.5 
 
 
Figure 24: BPI chromatogram (ESI+) from the first purification of compounds considered responsible for the observed activity 
from the bacterial strain AM. The compounds were separated using a RP 18 column with an elution gradient of MilliQ water 
and acetonitrile, both containing 0.1% (v/v) FA, and a flow rate of 6 mL/min (50% B to 100% B in 15 minutes. The fractions 
were collected by mass triggered fractionation. As seen in the chromatogram, the compound AM-23-404 is eluting earlier 
than the compound AM-24-404, indicating that the first mentioned compound has a more polar character.   
The fractions were further purified in a second round of preparative HPLC-MS to obtain 
compounds of sufficient purity for structure elucidation by NMR. Purification was performed 
utilising the fluoro-phenyl column and the fractions were collected using mass triggered 
fractionation. The weight of the dried fractions is listed in Table 24, and the BPI chromatograms 
from these separations can be seen in Fig. 25.  
Table 24: Isolated compounds from the bacterial strain AM and their dry weight after second purification. 








Figure 25: BPI chromatogram (ESI+) from the second purification round of compounds of interest from the bacterial strain 
AM. The compounds were separated using a fluoro-phenyl column with an elution gradient of MilliQ water and ACN, both 
containing 0.1% (v/v) FA, and a flow rate of 6 mL/min (50% B to 100% B in 15 minutes). The fractions were collected by mass 
triggered fractionation.  
5.8 Bioactivity screening of the isolated target compounds 
 
The isolated compounds were screened for antibacterial activity in a growth inhibition assay. 
The compounds were tested against the pathogenic bacterial strain Streptococcus type B in the 
concentrations 50, 10 and 5 µg/mL. Fraction TS-7-mix was active against the test strain at the 
highest and the lowest concentrations, while none of the other tested compounds displayed 
activity and were thus excluded from further work. The compounds most likely responsible for 
the observed activity in the fraction TS-7-mix were purified further, and the isolated compounds 
were re-tested for antibacterial activity against the same test strain at a final concentration of 50 
µg/mL. The compound TS-7-281 was found to be responsible for the activity in this fraction as 
none of the other compounds were deemed active against the test strain. This compound as well 
as the compound TS-7-558, despite not being active, were submitted to structure elucidation by 
NMR. The compounds were also screened for anticancer activity against the human melanoma 
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celle line A2058 at a final concentration of 50 µg/mL, and the compound TS-7-281 was found 
to be active. The compound TS-7-317 was excluded from further work as it was not active and 
it was suspected of being a contaminant.  
5.9 Structure elucidation of target compounds 
 
Three isolated compounds from the bacterial strain TS and three isolated compounds from the 
bacterial strain AM were submitted to NMR in an attempt to achieve their full structures. The 
isolated compounds submitted to NMR, the criteria for why, their calculated elemental 
compositions and hits given in databases can be seen in Table 25. However, the chemical 
structure of the compounds was not achieved due to compound degradation and unforeseen 
downtime on the NMR at the end of project time, respectively. 
Table 25: Overview of isolated compounds from fraction 5 of the bacterial strains TS and AM, that were submitted for 
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6.1 Cultivation and extraction from the bacterial strains 
 
Three marine bacteria (AM, PM and TS) were cultivated. AM and PM are classified under the 
class Gammaproteobacteria that belongs to the phylum Proteobacteria, the bacterial class that 
appears in most marine environments (104), whereas TS is a bacterium within the class 
Alphaproteobacteria that belongs to the phylum Proteobacteria as well, and is considered one 
of the greatest and most extensively studied groups within bacteria (105). 
The bacteria were cultivated in different culture media with varying nutrient sources. It was 
attempted to make them grow in various culture media previously, and it was discovered that 
the media used were most suitable for these bacteria to grow in and produce bioactive secondary 
metabolites. After isolation, the bacteria have been cultivated in four different media, extracted 
via HP-20 solid phase extraction, flash-fractionated and tested in anticancer assays, 
antimicrobial assays and anti-inflammatory assays. That screening-campaign within the 
“Pharmasea”-project executed at Marbio was the basis for this master thesis, and the culture 
conditions that have shown activity or the highest activity were selected for the bacteria 
investigated in the present thesis. However, establishment of novel and further development of 
existing isolation and cultivation methods may increase the diversity of isolates, shorten the 
time of cultivation to attain appreciable cell mass for higher yields and production of secondary 
metabolites (106).  
 
Extraction is the essential first step in NP drug discovery, as it is necessary to extract the coveted 
chemical compounds from raw materials for further separation and characterisation (107). The 
selection of an appropriate extraction method is driven by the amount and nature of the 
compounds to be isolated in the extraction process, as well as the matrix from which they are 
to be extracted (108). The compounds synthesised by bacteria are not known in advance, and 
thus it becomes a challenge to select a suitable extraction method in order to extract all 
compounds of interest. Solid-phase extraction with Diaion HP-20 resin and methanol is one of 





It was cultivated 12 flasks, each containing 300 mL, of the bacterial strain PM, which gave an 
exctract yield of 18.33 g. TS and AM were cultivated in 21 flasks each, resulting in extraction 
yields of 17.75 and 6.05 g, respectively. As can be seen, PM had an overall higher extraction 
yield, whereas AM had the smallest yield of the three marine bacteria. Moreover, the yield per 
liter culture of PM was higher than of TS. However, the incubation period was longer for PM. 
This indicates that the crude extract’s yield is dependent on the bacterial species and their 
incubation time. High extract weight however does not necessarily reflect high production of 
secreted secondary metabolites, as growth media components and primary metabolites may also 
be extracted. This was experienced in this thesis with the bacterial strain TS, where most of the 
compounds, including TS-4-652, TS-4-265 and TS-7-889, were found to be growth media 
components and not produced by the bacterial strain. Hence, the bacterium with the highest 
weight is not necessarily a better producer of secondary metabolites. Perhaps the bacterial strain 
AM produces low molecular weight secondary metabolites which are better adsorbed by the 
resin, whereas extracts of TS and PM contains higher amounts of growth media components.  
6.2 Pre-fractionation of the extracts  
 
The extracts from the bacterial strains were pre-fractionated into six fractions each prior to 
bioactivity screening. Only fraction 5 was found to be active in the bioactivity screening, and 
the yield obtained of this fraction was generally low. However, as can be seen in the results, 
fraction 5 from the extract of PM had a high yield since it was not completely dry. The fraction 
was placed in the speedvac for several days in an effort to remove organic solvent, and 
freezedried to remove the remaining water, but it was still some liquid left. Due to the low 
weight of the fraction from extracts of the other two bacterial strains, the potentially promising 
compounds of interest were present in too small quantities to carry out isolation, bioactivity 
confirmation and structure elucidation. Hence, new cultures were prepared to obtain sufficient 
material of the target compounds. When preparing new cultures, it is important that the same 
parameters are used for cultivation as the original culture, in order for the bacteria to produce 
the same active compounds of interest, as observed in this thesis. One of the major obstacles 
associated with the utilisation of MNPs in drug discovery are the difficulties in obtaining 
sufficient amounts of material pure enough for bioactivity confirmation and structure 
elucidation. Utilising marine bacteria is however an advantage in contrast to marine 
invertebrates, because if sufficient material is not obtained, it is feasible to prepare new cultures 
which mimic the same conditions in order to trigger the bacteria to produce the same 
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compounds. As for invertebrates, if a compound is obtained in small quantities and its 
availability is restricted or if the invertebrate is collected in regions difficult to access, re-supply 
becomes arduous.  
6.3 Bioactivity screening of flash fractions  
 
The flash fractions were analysed for antibacterial properties against six bacterial strains and 
screened for anticancer properties against the cancer cell line A2058. Cut-off values were used 
to assess whether a fraction was active or not, making it easy to quickly select which fractions 
to prioritise for further studies. The questionable fractions were treated as active and further 
analysed as these fractions may contain bioactive compounds of interest that will not be 
discovered if they are excluded from further investigation. Some compounds are of low potency 
and consequently show activity only at high concentrations, as observed with the flash fraction 
AM-5 which exhibited activity against MRSA at 100 and 50 µg/mL (Fig. 12 and 13), while the 
activity was lost at 25 µg/mL (Fig. 14). Hence, it is appropriate to carry out bioassays at various 
concentrations to perceive whether the compounds lose activity at lower concentrations.  
No activity was reported against Gram-negative test strains in this project, which is consistent 
with previous results from Marbio, where activity against these bacteria are rarely observed. 
The need for novel antibiotics against Gram-negative bacteria is growing, as there is an 
immense problem with resistance observed for many of these organisms. Gram-negative 
bacterial infections may be difficult to treat due to the presence of porins and efflux pumps in 
their outer membrane, which can result in limited influx and increased outflux of antibiotics 
used during infections. Hence, it is important to discover novel antibiotics that are able to tackle 
the resistance of these bacteria (110). Cultivating the marine bacteria with Gram-negative 
bacteria could possibly trigger the production of secondary metabolites that are selectively 
active against these in a defence mechanism. However, the need for novel antibiotics against 
Gram-positive bacteria is also urgent, as there are several human pathogens amongst these 
organisms which are causing global resistance challenges, such as MRSA (111). Consequently, 
the research towards discovering novel antibiotics is becoming more important.   
As can be seen in the results (Fig. 15), only fraction 5 from the extracts of PM and AM were 
deemed active against the A2058 cancer cell line. The activity was tested in a single high 
concentration (100 µg/mL), and the high activity observed in these fractions could be due to 
the high concentration. Substances that only display anticancer effects at very high 
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concentrations are unlikely to be sufficiently selective for cancer cells, because effects on other 
normal cells become increasingly more probable with higher concentrations. Hence, promising 
anticancer substances are usually highly potent and show activity at low concentrations. The 
fractions were however selected for further investigation in order to identify the compounds 
responsible for the observed activity and to find out if they were active at lower concentrations 
as well.  
6.4 Re-fractionation of active flash fractions and bioactivity screening of 
subfractions 
 
The active flash fractions were re-fractionated into 40 subfractions that were screened for 
antibacterial and anticancer activity. Subfractions are less complex than flash fractions, making 
it easier to identify compounds potentially responsible for the observed activity in bioassays for 
further investigation, as seen in this thesis. Moreover, by comparing active and inactive 
fractions, it was possible to select promising compounds for isolation and bioactivity 
confirmation. Compounds that were present in both active and inactive subfractions, in similar 
quantities, were excluded from further work. For instance, a compound with m/z 297.30 was 
observed in both the active subfraction TS-25 and the inactive subfraction TS-24, and was 
consequently excluded from further work. The subfractions were screened for antibacterial 
activity against the bacterial strains E. coli and Streptococcus type B. These bacterial strains 
were selected as representatives of Gram-negative and Gram-positive strains, respectively, 
because E. coli is the most-studied bacterial strain and Streptococcus type B is known as the 
most sensitive bacterial strain, according to the experience of Marbio, so if the subfractions are 
not active against this strain, they are probably not active against any other strains either. 
Although flash fraction 5 from the extract of TS did not display antibiotic activity against the 
pathogen Streptococcus type B, some of the subfractions did. This indicated that the active 
compounds either were present at low and not detectable concentrations or their effects were 
masked by interfering compounds. This illustrates the importance of re-fractionating the flash 
fractions into several less complex subfractions for further study.  
Anticancer activity of the subfractions was evaluated against the human melanoma cancer cell 
line A2058, as this is the most sensitive cell line upon previous experience in Marbio. Activity 
was only observed in some subfractions from the bacterial strain PM at high concentration, thus 
the activity observed in flash fractions was confirmed to be due to the high concentration. RLs 
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may be responsible for the observed activity, as the same subfractions were active in 
antibacterial screening where RLs were observed and believed to be responsible for the activity.  
It is important to mention that the re-fractionation process lacks the exact knowledge of tested 
concentration. It gives just qualitative information about the active fractions from which the 
active compounds may further be identified. Organic salts, lipids etc. may cause inspecific 
activity also due to synergic effects and especially if they are present in high concentrations. In 
such cases it can be a practical approach to dilute the re-fractionation to point out the most 
active fractions.  
In the MS chromatogram of some active subfractions from the bacterial strains no compounds 
were detected, the compounds were however seen in the UV/Vis detector. This may indicate 
that the compounds have very strong chromophores, but are poorly ionised by ESI. These 
results show the importance of using a UV/VIS in series with a MS detector, as the two detectors 
provide complementary information. 
6.5 Dereplication of active subfractions from bioactivity screening 
 
In this thesis, 13 active subfractions (from three different bacterial strains) from the antibacterial 
activity screening were dereplicated using UHPLC-HR-MS to identify the compounds 
responsible for the observed bioactivity. An elemental composition was calculated for 
compounds believed to be active and database searches were performed. Dereplication 
proactively reduced the number of subfractions entering the isolation process, saving valuable 
time and resources (112). The active subfractions PM-19, PM-25, PM-27 and PM-29 contained 
known bioactive RLs, hence, further work with these subfractions was terminated. RLs were 
observed in the active subfractions AM-23, AM-24 and AM-25 as well, and to our knowledge 
they have not been reported from this bacterial strain previously (113). The subfraction TS-25 
contained target compounds that appeared to be novel, so they were selected for isolation. The 
subfraction TS-19 contained a di-halogenated compound of interest that was selected for 
isolation. The subfractions AM-23 and AM-24 contained two compounds with the same masses 
but different retention times, that were suspected to be isomers and they were selected for 
isolation and structure elucidation to confirm this. The subfraction AM-25 contained a target 
compound that was selected for isolation as it was not identified in dereplication. In this thesis, 
it was possible to terminate further work with the fractions containing previously reported 
bioactive compounds (rhamnolipids) by doing dereplication prior to isolation.  
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Utilisation of UHPLC-HR-MS for dereplication brings challenges, such as the formation of 
adducts, that can affect the identification of compounds. As can be seen in the results, the RLs 
were found as sodium adducts, complying with previously isolated RLs in retention time and 
mass. Sodium adducts are frequently observed since the bacteria are grown in media 
containing filtered seawater.  
6.6 Isolation and bioactivity confirmation of target compounds  
 
The target compounds should be purified and isolated from the sample matrix in order to 
elucidate their chemical structures. To isolate target compounds from a sample consisting of 
several other compounds, it is important to select a suitable column and mobile phase gradient. 
Various columns can be used to obtain sufficient separation of target compounds and remove 
impurities utilising preparative HPLC-MS. The columns differ in packing material and may 
differ in particle size and column dimensions as well, giving rise to different retention of the 
compounds in a sample. In this project, three RP columns were utilised for HPLC separation 
(Fig. 26). The columns X-Terra® and SunFireTM have a C18 hydrocarbon attached to their 
silica backbone, they however result in different separations due to differences in particle size 
and in silica-modifications. The Fluoro-Phenyl column incorporate multiple retention 
mechanisms, such as dispersion, shape selectivity, dipole, and pi-pi (π-π) interactions, making 
it a powerful tool for difficult separations, including those for small polar compounds and basic 
analytes. This column provides high selectivity by incorporating highly electronegative fluorine 
atoms on a phenyl ring (114). The compounds were isolated in only two rounds of HPLC 
separation in order to avoid losing much of the material, as at least 1 mg of material is required 
for NMR depending on structure complexity of the compounds. As seen in the results, the 
compound TS-7-317 was however isolated in only one round, since it was later suspected to be 
a contaminant based on the results seen in the BPI chromatograms from the second purification 
illustrated in Fig. 21.  
By varying the use of columns in the first and second rounds of isolation in this thesis, target 
compounds of sufficient purity were obtained. The columns were selected based on prior 
experience with separation of target compounds, where a RP C18 column normally is used in 
the first round of isolation as a wide range of compounds are isolated with this column, while 
in the second round of isolation a more selective column is used to selectively isolate the target 




Figure 26: The column material of the three different RP columns utilised in this work. The circles with different colours 
represent the various silica backbone of the columns (115).  
Compounds should be re-dissolved in a suitable solvent for the second round of isolation. 
However, this might become a challenge since the nature of the isolated compounds are 
unknown. Nevertheless, the retention times of the compounds provide an indication of their 
hydrophobicity and hydrophilicity, as the polar compounds elute earlier than the non-polar 
compounds in a RP C18 column used in the first round of isolation. Methanol is a preferred 
solvent in order to re-dissolve NPs, as it should dissolve most of these compounds. However, a 
‘’trial-and-error’’ approach should be carried out if the compounds are not soluble in methanol 
(74). As experienced in this thesis, the compounds TS-19-227, AM-23-404, AM-24-404 and 
AM-25-418 were found difficult to re-dissolve for the second round of isolation, and they were 
tested in several solvents in an effort to dissolve them. After all, the compound TS-19-227 was 
found to dissolve best in tetrahydrofuran, acetonitrile and MilliQ water, whereas the other 
compounds were found to dissolve best in the mobile phase gradient in which they were eluting 
in the first round of isolation.  
Some interfering compounds may lead to false positive results, so there is no assurance that 
isolated compounds are responsible for the observed biological activity detected in the 
screening. It is therefore, a possible strategy to screen the isolated compounds for bioactivity 
prior to NMR analysis if sufficient material is obtained, in order to confirm their activities with 
certainty. Importantly, by confirming bioactivity before submitting compounds suspected to be 
active for structure elucidation with NMR, time and resources where saved as compounds found 
to not be active were excluded from further study. For instance, the two compounds, TS-25-
398 and TS-25-386, which were suspected to be responsible for the observed activity in 
subfraction 25, were found not to be active. They were tested for bioactivity in a high 
concentration (50µg/mL) against one of the most sensitive bacterial strains, and as they were 
not active it was decided to exclude them from further study. It might be that a potent compound 
present in a very low concentration that actually is responsible for the observed bioactivity. The 
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other compounds present in this fraction should be isolated and screened for bioactivity in order 
to confirm this. This is however a time- and resource consuming process to carry out in this 
thesis. The activity may possibly also be due to a synergic effect from several compounds 
present in the fraction.  
For fraction TS-7 it was difficult to identify the compounds responsible for the bioactivity, and 
as isolation is time and resource consuming, it was decided to isolate several compounds of 
interest in a fraction named TS-7-mix (Fig. 20), and screen them for antibacterial activity to 
confirm potential activity before any further isolation of the compounds. The fraction was found 
to be active against the bacterial strain Streptococcus type B and was hence dereplicated to 
identify the compounds most likely responsible for the observed activity. By comparing this 
subfraction with that of the medium used in the cultivation of TS, in dereplication, it was 
possible to avoid selecting growth media components for isolation and isolate the compound 
responsible for the observed bioactivity. The compound TS-7-281 was found to be responsible 
for the bioactivity, and it was active in both antibacterial and anticancer assays. Therefore, it 
was submitted to NMR as it was not identified in dereplication, and appeared thus to be novel. 
The BPI chromatogram of the compound can be seen in Appendix, see A1. The compound TS-
7-558 was submitted to NMR as well, despite not being active, as it may be active in other 
bioassays or its chemical properties may be of interest.  
A di-halogenated compound was observed in the inactive subfraction TS-19. The compound 
was found interesting despite not being active in the bioassays performed in this thesis, as it 
may be active in other bioassays and the presence of halogens in pharmaceuticals is known to 
affect their activity by altering their electronic and steric properties, improving their membrane 
permeability, slowing their catabolism and improving their binding affinity with their targets 
(116). According to HR-MS, this compound is probably an aminopyrrolnitrin, and if so, this is 
the first time an aminopyrrolnitrin is isolated from this bacterial strain. Aminopyrrolnitrin is a 
precursor of pyrrolnitrin which is a previously reported NP produced by the bacterial strain 
Pseudomonas sp., and has known antifungal activity (117). The compound was however 
selected for isolation and structure elucidation with NMR, as it was not possible to identify it 
with high certainty in dereplication. This compound was submitted to NMR before performing 
further bioassays to investigate its activity, as only a small quantity of the compound was 
obtained after isolation and as much as possible was required for NMR.  
The compounds AM-23-404 and AM-24-404 were as mentioned selected for isolation as they 
were believed to be isomers. Isomers are of interest in NP drug research, as they may differ in 
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their pharmacokinetic and pharmacodynamic properties, and consequently result in different 
bioactivities. Moreover, isolation of isomers which are strictly related compounds is highly 
appreciated, as it can be used to assess structure-activity relationships (SAR) (118). The 
compound AM-25-418 was believed to be responsible for the bioactivity in subfraction AM-25 
and was selected for isolation to confirm this. These compounds were submitted to NMR before 
investigating their activities due to restricted time with the thesis and to ensure the achievement 
of full structures prior to further investigation.  
In the active subfractions TS-3, TS-26 and TS-27, it was not detected any compounds of interest 
for isolation. The compounds eluting in the beginning of the gradient in a RP-HPLC separation 
are highly hydrophilic, such as sugars or amino acids, while the compounds eluting in the end 
of the gradient are in general highly lipophilic such as phospholipids. Promising bioactive 
compounds to be used as pharmaceuticals have generally intermediate lipophilicity and are thus 
eluting in the middle of the gradient. Highly hydrophilic compounds have low bioavailability 
as they cannot cross biological membranes, and highly lipophilic compounds can accumulate 
in the bloodstream as they do not dissolve well. Therefore, a desirable property of an effective 
pharmaceutical is a balanced hydrophilic/lipophilic character. However, it is not proven that the 
compounds responsible for the observed activity in these fractions are sugars, amino acids or 
phospholipids. Several growth media components were observed in the fractions that possibly 
could be responsible for the bioactivity. Observed activity may also be due to a synergic effect 
of several compounds in the fractions. It is nonetheless not possible to predict the respective 
compounds without further investigation, which is time consuming and not appropriate in this 
work. As experienced in this work, identifying compounds causing observed bioactivity within 
fractions is one of the major challenges in NP drug discovery, as most of the time, the 
compounds suspected of being active are found to be inactive.  
6.7 Structure elucidation of target compounds by NMR 
 
The bioactive and di-halogenated compounds were prioritised for NMR analysis, since they 
were the most promising and interesting among the isolated compounds. However, only the di-
halogenated compound was analysed by NMR. No NMR analysis was conducted for the other 
compounds, due to unforeseen downtime on the NMR at the end of project time. Also due to 
the time limit we had, we were not able to conduct further analysis. Therefore, no NMR data is 
available for these. This will be part of further work.  
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The di-halogenated compound TS-19-227 was not sufficiently pure to enable elucidation of the 
structure. NMR spectra of the compound showed only weak signals and purity of the compound 
was roughly 10-15%, implicating presence of high impurities which unable characterisation of 
the target compound. Therefore, it was difficult to interpret the spectra. However, NMR 
analysis could confirm the presence of two halogens in the structure. To our knowlegde, this is 
the first time a di-halogenated compound with potential bioactivity is isolated from the bacterial 
strain TS. The weak signals were suspected of being a result of poor solubility in DMSO, there 
was however no attempt to dissolve it in other solutions, as more compound in pure form was 
needed to conduct further NMR analysis. Mass spectrometry may allows conclusions about the 
compound of interest when there is not enough sample for an NMR analysis. The fragmentation 
pattern of a molecule in mass spectrometry can provide useful clues about the compounds 
structure and identity, it however does not prove the structure and thus, a full synthesis and 
characterisation would be needed as final proof (119). The compound was run in positive and 
negative ESI mode, and the respective MS chromatograms can be seen in Appendix, see A2. 
Most of the compounds detected in positive ESI mode were found to be di-chlorinated 
compounds based on their mass spectra, and were therefore suspected of being degradation 
products of the target compound which was not detected in the chromatogram. It is known that 
extracts from any sort of organism may consist of highly labile compounds which may 
decompose at any stage in the purification process or storage, and this might apply to this 
compound. Factors that may lead to degradation of compounds include heat, light, air, pH and 
solvents.   
The purification process of the target compound was repeated, and it was run in HR-MS again 
to confirm wheter if it was degraded. The target compound was not detected, another di-
halogenated compound with m/z 236.99, named TS-236, was however seen in the 
chromatogram (Appendix; A3). The calucalated elemental composition of the compound was 
C11H6N2Cl2, giving several hits in the databases. All the suggested compounds had a cyano 
group in common, but their position of the two chlorine atoms was different. One of the 
suggestens was the compound fenpicionil, and it seems to be a degradation product of the target 
compound that is suspected of being aminopyrrolnitrin, based on its structure and as it was not 
detected in flash fraction 5. The compounds are depicted in Fig. 27, and as can be seen, the 
primary amine of aminopyrrolnitrin is probably oxidised to form a nitrile (fenpicionil) in several 
stages. Primary amines are quite reactive because of their basicity as well as their 
nucleophilicity, so they are involved in oxidation and hydroxylation reactions in many chemical 
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and biological systems. Aromatic amines are additionaly extremely reactive in electrophilic 
aromatic substitution. The mechanism for the occurred reaction is difficult to predict without 
further investigation, as the synthesis of nitriles from primary amines can take place in several 
ways. It might be that the target compound is involved in a chemical reaction with one or several 
of the solvent used in the re-fractionation and isolation process, such as acetonitrile and formic 
acid, DMSO and methanol were not options as these were used in the flash fractionation and to 
dissolve the flash fractions without affecting the compound since we have found 227 but no 
236 within the MS profile of our flash fractions, indicating that to that step of the preparation 
no degradation has taken place. The target compound might also be involved in chemical 
reactions with other compounds present in the fraction. A possible reaction mechanism might 
be that the primary amine is involved in a reaction with formic acid or other unknown 
compounds within the fraction, to form an amide that is further dehydrated by acetonitrile into 
a nitrile (120). Another possible mechanism behind this reaction might be transition metal 
catalysed cyanation of aryl halides (121). However, the additional purification (employing the 
same method) with subsequent UHPLC-MS/MS analysis proved that the purification itself 
worked and the purity would have been sufficient for NMR. The compound itself is unstable 
and the test of different solvents to dissolve the compound for NMR might even have increased 
its decomposition. 
Subfraction TS-19 was analysed with HR-MS to investigate if the target compound was present, 
and to verify whether it was decomposed or not. The respective BPI chromatogram can be seen 
in Appendix, see A4. As can be seen, the compound was detected. However, the compound 
which was suspected to be a product of decomposition was also detected. Moreover, several 
other compounds with similar structures as the target compound were detected, indicating 
decomposition had taken place. This proves that the target compound gradually starts to 
decompose in the re-fractionation process. The structures given in Fig. 27 are of course hits 
generated by MS data, however the results of the Chemspider search and the mass difference 































Six compounds were isolated from two different bacterial strains using the bioassay guided 
isolation approach, and their structures were attempted elucidated by NMR spectroscopy. One 
bioactive compound was isolated from the bacterial strain TS. The compound was active against 
the bacterial strain Streptococcus type B and the melanoma cell line A2058, at a final 
concentration of 50 µg/mL. Moreover, a di-halogenated compound was also isolated from this 
bacterial strain, and it was attempted characterised by NMR without results. The compound 
was degraded, and it was therefore difficult to interpret the NMR spectra. RLs were observed 
in fractions from the bacterial strain AM for the first time.  
The results from this work illustrate 
➢ That bioprospecting of marine bacteria enables isolation of bioactive secondary 
metabolites, and previously reported compounds in novel species. 
➢ The importance of dereplication to terminate samples that should not be prioritised in 
a bioprospecting process. 
➢ The importance of isolating compounds in several preparative HPLC(-MS-DAD) 
rounds in order to obtain compounds of sufficient purity.  
➢ That compounds of interest might decompose during the isolation process. Here the 
suitabillity of HPLC-MS to check purity and stabillity of the compounds of interest 

















In this work process, several compounds were isolated and screened for bioactivity to confirm 
their activities. Six isolated compounds (Table 25) were found interesting and submitted to 
NMR spectroscopy for identification. NMR analaysis was only performed for the compound 
TS-19-227, the structure of the compound was not elucidated since it was degraded. The 
compound TS-236 was found to be a degradation product of this compound, and it will be 
analysed by NMR spectroscopy, as it can give an indication of what may have contributed to 
degradation of the target compound. The target compound will be attempted structure 
elucidated at a later stage, and screened for bioactivity in several assays to characterise its 
potential activity. The compound TS-7-281 was found to be active in antibacterial and 
anticancer assays at a final concentration of 50 µg/mL, further work will be done on determinig 
the IC50 value of the compound to asses its potency. The chemical structure of this compound 
was not achieved during this work, but NMR analysis will be performed in future work. NMR 
analysis will be performed for the compounds AM-25-418, AM-24-404 and AM-23-404 as 
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A1: UHPLC-QToF-MS of the compound TS-7-281 
 
 
Figure 28: Left) HR-MS BPI chromatogram (ESI+) of fraction TS-7-281 after the first round of isolation. The fraction was 
injected into a Waters Aquity UPLC® (2.1x100 mm, 1.7 µm) column, and a mobile phase gradient og MilliQ and Acetonitrile, 
both with 0.1% FA was used with a flow rate of 0.45 ml/min. Right) The mass spectrum of the compound TS-7-281. No 














A2: UHPLC-QToF-MS of the compound TS-19-227 after NMR analysis 
 
 
Figure 29: HR-MS BPI chromatograms (ESI+ and ESI-) of the di-chlorinated compound 227.  The compound was injected into a 
Waters Aquity UPLC® (2.1x100 mm, 1.7 µm) column, and a mobile phase gradient og MilliQ and Acetonitrile, both with 0.1% 
FA was used with a flow rate of 0.45 ml/min. The chromatograms show that the target compound is not detected and most 
of the compounds detected in positive ESI mode were di-chlorinated, such as the compounds with retention times 3.70, 4.47, 
5.18, 5.73 and 7.31. This could imply that the target compound is degraded during the isolation process or it could be 









A3: UHPLC-QToF-MS of the compound TS-19-227 after a new attempt of isolation 
 
 
Figure 30: Left) HR-MS BPI chromatogram (ESI+) of the di-chlorinated compound 227. The compound was injected into a 
Waters Aquity UPLC® (2.1x100 mm, 1.7 µm) column, and a mobile phase gradient og MilliQ and Acetonitrile, both with 0.1% 
FA was used with a flow rate of 0.45 ml/min. The chromatogram show that the compound 227 is not detected, another 
compound with m/z 236.99 was however detected as seen. Right) The mass spectrum of the compound 236.99. As can be 
seen the compound is di-chlorinated, and this compound was not found in the flash fraction 5. Therefore, it was suspected of 












A4: UHPLC-QToF-MS of subfraction TS-19  
 
 
Figure 31: Left) HR-MS BPI chromatogram (ESI+) of subfraction TS-19. The subfraction was injected into a Waters Aquity 
UPLC® (2.1x100 mm, 1.7 µm) column, and a mobile phase gradient og MilliQ and Acetonitrile, both with 0.1% FA was used 
with a flow rate of 0.45 ml/min. The chromatogram show that the compound 227 is detected, and the compound TS-236, 
suspected of being a degradation product of this compound is also detected. Right) The mass spectra of the compound TS-
19-227 and TS-236. This proves that the compound TS-236  is a degradation product of the target compound as the 
compound was not detected in flash fraction 5, and their structures are similar based on MS data.   
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